WO2001057510A2 - Electrochemical methods and devices for use in the determination of hematocrit corrected analyte concentrations - Google Patents

Electrochemical methods and devices for use in the determination of hematocrit corrected analyte concentrations Download PDF

Info

Publication number
WO2001057510A2
WO2001057510A2 PCT/US2001/002465 US0102465W WO0157510A2 WO 2001057510 A2 WO2001057510 A2 WO 2001057510A2 US 0102465 W US0102465 W US 0102465W WO 0157510 A2 WO0157510 A2 WO 0157510A2
Authority
WO
WIPO (PCT)
Prior art keywords
time
concentration
analyte
preliminary
hematocrit
Prior art date
Application number
PCT/US2001/002465
Other languages
French (fr)
Other versions
WO2001057510A3 (en
Inventor
Timothy J. Ohara
Mahyar Z. Kermani
Original Assignee
Lifescan, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to PL01358492A priority Critical patent/PL358492A1/en
Priority to CA002398203A priority patent/CA2398203A1/en
Priority to DE60116056T priority patent/DE60116056T2/en
Priority to IL14966201A priority patent/IL149662A/en
Priority to JP2001556308A priority patent/JP2003521708A/en
Priority to EP01905055A priority patent/EP1252514B1/en
Priority to AT01905055T priority patent/ATE313794T1/en
Priority to KR1020027009882A priority patent/KR20020077409A/en
Application filed by Lifescan, Inc. filed Critical Lifescan, Inc.
Priority to AU32974/01A priority patent/AU783311B2/en
Priority to MXPA02005797A priority patent/MXPA02005797A/en
Publication of WO2001057510A2 publication Critical patent/WO2001057510A2/en
Publication of WO2001057510A3 publication Critical patent/WO2001057510A3/en
Priority to HK03101950.3A priority patent/HK1049881B/en
Priority to AU2006200073A priority patent/AU2006200073A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/28—Electrolytic cell components
    • G01N27/30—Electrodes, e.g. test electrodes; Half-cells
    • G01N27/327—Biochemical electrodes, e.g. electrical or mechanical details for in vitro measurements
    • G01N27/3271—Amperometric enzyme electrodes for analytes in body fluids, e.g. glucose in blood
    • G01N27/3274—Corrective measures, e.g. error detection, compensation for temperature or hematocrit, calibration
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose

Definitions

  • the field of this invention is analyte determination, particularly electrochemical analyte determination and more particularly the electrochemical determination of blood analytes.
  • Analyte detection in physiological fluids e g blood or blood derived products
  • Analyte detection assays find use in a variety of applications, including clinical laboratory testing, home testing, etc., where the results of such testing play a prominent role in diagnosis and management in a variety of disease conditions
  • Analytes of interest include glucose for diabetes management, cholesterol, and the like.
  • analyte detection protocols and devices for both clinical and home use have been developed.
  • an electrochemical method One type of method that is employed for analyte detection is an electrochemical method.
  • an aqueous liquid sample is placed into a reaction zone in an electrochemical cell comprising two electrodes, i e a reference and working electrode, where the electrodes have an impedance which renders them suitable for amperometric measurement.
  • the component to be analyzed is allowed to react directly with an electrode, or directly or indirectly with a redox reagent to form an oxidisable (or reducible) substance in an amount corresponding to the concentration of the component to be analyzed, i e. analyte
  • the quantity of the oxidisable (or reducible) substance present is then estimated electrochemically and related to the amount of analyte present in the initial sample
  • the hematocrit of the sample can be a source of analytical error in the ultimate analyte concentration measurement
  • hematocrit can slow the equilibration chemistry in the electrochemical cell and/or slow the enzyme kinetics by increasing the sample viscosity in the cell, thereby attenuating the time current response and causing analytical error
  • blood filte ⁇ ng membranes are employed to remove red blood cells and thereby minimize the hematoc ⁇ t effect
  • Patent documents of interest include 5,942,102 and WO 97/18465
  • the physiological sample is introduced into an electrochemical cell having a working and reference electrode
  • a first elect ⁇ c potential is applied to the cell and the resultant cell current over a first pe ⁇ od of time is measured to determine a first time-current transient
  • a second elect ⁇ c potential of opposite polarity is then applied to the cell and a second time-current transient is determined
  • the preliminary concentration of the analyte (C 0 ) ⁇ s then calculated from the first and/or second time-current transients
  • This preliminary analyte concentration, less a background value is then multiplied by a hematoc ⁇ t correction factor to obtain the analyte concentration in the sample, where the hematocrit correction factor is a function of the preliminary analyte concentration and the ratio of 2 current values ( ⁇ ) within the time-current transient of the electrochemical cell
  • the subject methods and devices are suited for use m
  • Methods and devices for determining the concentration of an analyte in a physiological sample are provided.
  • the physiological sample is introduced into an electrochemical cell having a working and reference electrode.
  • a first electric potential is applied to the cell and the resultant cell current over a first period of time is measured to determine a first time-current transient.
  • a second electric potential of opposite polarity is then applied to the cell and a second a time-current transient is determined.
  • the preliminary concentration of the analyte is then calculated from the first and/or second time-current transient.
  • This preliminary analyte concentration, less a background value, is then multiplied by a hematocrit correction factor to obtain the analyte concentration in the sample, where the hematocrit correction factor is a function of the preliminary analyte concentration and the variable ⁇ of the electrochemical cell.
  • the subject methods and devices are suited for use in the determination of a wide variety of analytes in a wide variety of samples, and are particularly suited for use in the determination of analytes in whole blood or derivatives thereof, where an analyte of particular interest is glucose.
  • the subject methods will be described first followed by a review of a representative device for use in practicing the subject methods.
  • the subject invention provides a method for determining a hematocrit corrected analyte concentration value in a physiological sample.
  • hematocrit corrected analyte concentration is meant that the analyte concentration value determined using the subject methods has been modulated or changed to remove substantially all contribution of hematocrit to the value.
  • the concentration value that is determined using the subject methods has been modified so that any contribution to the value from the hematocrit of the sample that would be present in the value but for the practicing of the subject methods is removed.
  • the hematocrit signal is deconvoluted from the analyte signal in the subject methods, and only the analyte signal is employed in arriving at the final hematocrit corrected analyte concentration.
  • the first step in the subject methods is to introduce a quantity of the physiological sample of interest into an electrochemical cell that includes spaced apart working and reference electrodes and a redox reagent system.
  • the physiological sample may vary, but in many embodiments is generally whole blood or a derivative or fraction thereof, where whole blood is of particular interest in many embodiments.
  • the amount of physiological sample, e.g. blood, that is introduced into the reaction area of the test strip varies, but generally ranges from about 0.1 to 10 ⁇ L, usually from about 0.9 to 1.6 ⁇ L.
  • the sample is introduced into the reaction area using any convenient protocol, where the sample may be injected into the reaction area, allowed to wick into the reaction area, and the like, as may be convenient.
  • the subject methods may be used, in principle, with any type of electrochemical cell having spaced apart working and reference electrodes and a redox reagent system
  • the subject methods employ an electrochemical test strip.
  • the electrochemical test strips employed in these embodiments of the subject invention are made up of two opposing metal electrodes separated by a thin spacer layer, where these components define a reaction area or zone in which is located a redox reagent system.
  • the working and reference electrodes are generally configured in the form of elongated rectangular strips.
  • the length of the electrodes ranges from about 1.9 to 4.5 cm, usually from about 2.0 to 2.8 cm.
  • the width of the electrodes ranges from about 0.38 to 0.76 cm, usually from about 0.51 to 0.67 cm.
  • the reference electrodes typically have a thickness ranging from about 10 to 100 nm and usually from about 10 to 20 nm.
  • the length of one of the electrodes is shorter than the length of the other electrode, typically about 0.32 cm. The shorter electrode may be the working or reference electrode.
  • the working and reference electrodes are further characterized in that at least the surface of the electrodes that faces the reaction area in the strip is a metal, where metals of interest include palladium, gold, platinum, silver, iridium, carbon, doped tin oxide, stainless steel and the like.
  • the metal is gold or palladium.
  • each of the electrodes is generally made up of an inert support material on the surface of which is present a thin layer of the metal component of the electrode.
  • the thickness of the inert backing material typically ranges from about 51 to 356 ⁇ m, usually from about 102 to
  • the thickness of the metal layer typically ranges from about 10 to 100 nm and usually from about 10 to 40 nm, e.g. a sputtered metal layer.
  • Any convenient inert backing material may be employed in the subject electrodes, where typically the material is a rigid material that is capable of providing structural support to the electrode and, in turn, the electrochemical test strip as a whole. Suitable materials that may be employed as the backing substrate include plastics, e.g. PET, PETG, polyimide, polycarbonate, polystyrene, silicon, ceramic, glass, and the like.
  • a feature of the electrochemical test strips used in these embodiments of the subject methods is that the working and reference electrodes as described above face each other and are separated by only a short distance, such that the distance between the working and reference electrode in the reaction zone or area of the electrochemical test strip is extremely small.
  • This minimal spacing of the working and reference electrodes in the subject test strips is a result of the presence of a thin spacer layer positioned or sandwiched between the working and reference electrodes.
  • the thickness of this spacer layer generally should be less than or equal to 500 ⁇ m, and usually ranges from about 102 to 153 ⁇ m.
  • the spacer layer is cut so as to provide a reaction zone or area with at least an inlet port into the reaction zone, and generally an outlet port out of the reaction zone as well.
  • the spacer layer may have a circular reaction area cut with side inlet and outlet vents or ports, or other configurations, e.g. square, triangular, rectangular, irregular shaped reaction areas, etc.
  • the spacer layer may be fabricated from any convenient material, where representative suitable materials include PET, PETG, polyimide, polycarbonate, and the like, where the surfaces of the spacer layer may be treated so as to be adhesive with respect to their respective electrodes and thereby maintain the structure of the electrochemical test strip Of particular interest is the use of a die-cut double-sided adhesive st ⁇ p as the spacer layer
  • the electrochemical test strips used in these embodiments of the subject invention include a reaction zone or area that is defined by the working electrode, the reference electrode and the spacer layer, where these elements are described above Specifically, the working and reference electrodes define the top and bottom of the reaction area, while the spacer layer defines the walls of the reaction area
  • the volume of the reaction area is at least about 0 1 ⁇ L, usually at least about 1 ⁇ L and more usually at least about 1 5 ⁇ L, where the volume may be as large as 10 ⁇ L or larger
  • the reaction area generally includes at least an inlet port, and in many embodiments also includes an outlet port
  • the cross-sectional area of the inlet and outlet ports may vary as long as it is sufficiently large to provide an effective entrance or exit of fluid from the reaction area, but generally ranges from about 9 x lO ⁇ to 5 x 10 "3 cm 2 , usually from about 1 3 x 10 "3 to 2 5 x 10 "3 cm 2
  • a redox reagent system which reagent system provides for the species that is measured by the electrode and therefore is used to derive the concentration of analyte in a physiological sample
  • the redox reagent system present in the reaction area typically includes at least an enzyme(s) and a mediator
  • the enzyme member(s) of the redox reagent system is an enzyme or plurality of enzymes that work in concert to oxidize the analyte of interest
  • the enzyme component of the redox reagent system is made up of a single analyte oxidizing enzyme or a collection of two or more enzymes that work in concert to oxidize the analyte of interest
  • Enzymes of interest include oxidases, dehydrogenases, upases, kinases, diphorases, quinoproteins, and the like
  • the specific enzyme present in the reaction area depends on the particular analyte for which the electrochemical test strip is designed to detect, where representative enzymes include glucose oxidase, glucose dehydrogenase, cholesterol esterase, cholesterol oxidase, lipoprotein lipase, glycerol kinase, glycerol-3-phosphate oxidase, lactate oxidase, lactate dehydrogenase, pyruvate oxidase, alcohol oxidase, bilirubin oxidase, uricase, and the like
  • the enzyme component of the redox reagent system is a glucose oxidizing enzyme, e g a glucose oxidase or glucose dehydrogenase
  • the second component of the redox reagent system is a mediator component, which is made up of one or more mediator agents
  • mediator agents include fer ⁇ cvanide, phenazine ethosulphate, phenazine methosulfate, pheylenediamine, 1 -methoxy-phenazine methosulfate, 2,6-d ⁇ methyl-l,4-benzoqu ⁇ none, 2,5- d ⁇ chloro-l,4-benzoqu ⁇ none, ferrocene derivatives, osmium bipy ⁇ dyl complexes, ruthenium complexes, and the like
  • mediators of particular interest are fer ⁇ cyanide, and the like
  • agents that mav be present include divalent cations such as calcium chloride, and magnesium chloride, pyrroloquinohne quinone, types of surfactants such as Triton, Macol, Tetronic, Silwet, Zonyl, and Pluronic, stabilizing agents such as albumin, sucrose, trehalose, manmtol, and lactose
  • the redox reagent system is generally present in dry form
  • the amounts of the va ⁇ ous components may vary, where the amount of enzyme component typically ranges from about 1 to 100 mg/mL, usually from about 5 to 80mg/mL, and the amount of mediator component typically ranges from about 5 to 1000 mM, usually from about 90 to 900 mM
  • first and second time-current transients are obtained.
  • the first and second time-current transients are obtained by applying a constant elect ⁇ c potential to the cell and observing the change in current over a pe ⁇ od of time in the cell
  • first and second pulses are applied to the cell and the resultant time-current transients are observed
  • the first time-current transient is obtained by applying a constant electric potential or first pulse to the cell, e g between the working and the reference electrodes, and observing the change in current over time between the electrodes, l e change in cell current, to obtain the first time-current transient
  • the magmtude of the first applied electric potential generally ranges from about 0 to -0 6 N, usually from about -0 2 to -0 4 N
  • the length of time over which the current between the electrodes is observed to obtain the first time-current transient typically ranges from about 3 to 20 seconds, usually from about 4 to 10 seconds
  • the second time current is obtained by applying a second constant elect ⁇ c potential or second pulse, typically of opposite polarity from the first constant electric potential, to the electrodes and observing the change in current between the electrodes for a second period of time
  • the magnitude of this second constant electric potential typically ranges from about 0 to +0 6 N, usually from about +0 2 to +0 4 N, where in many embodiments the magnitude of the second electric potential is the same as the magnitude of the first electric potential.
  • the second time period typically ranges from about 1 to 10 seconds, usually from about 2 to 4 seconds.
  • the overall time period required to obtain the requisite first and second time-current transients, as described above, is relatively short in certain embodiments.
  • the total amount of time required to obtain the first and second time-current transients is less than about 30 seconds, usually less than about 20 seconds and more usually less than about 14 seconds.
  • the next step in the subject methods is to use the observed first and second time- current transients, obtained as described above, to determine: (a) the variable ⁇ of the electrochemical cell used in the subject methods; and (b) a preliminary analyte concentration for the analyte of interest in the sample.
  • the variable ⁇ employed in the subject methods is defined to describe the deviation of the electrochemical cell from ideality.
  • ⁇ should approach unity under ideal conditions, i.e. reagent equilibration and glucose reaction are complete before the end of the first pulse. Any of these conditions not being complete will cause the ratio to deviate fron non-unity values.
  • the denominator is defined as the average current over a short time period near the end of the first period of time, i.e. near the end of the application of the first electric potential or first pulse.
  • the short period of time from which the average current is determined typically ranges from .2 to 2 seconds, usually from about .2 to 1.5 seconds and more usually from about .2 to 1.25 seconds, where in many embodiments the short period of time is about .3 second.
  • the average current is determined at a time near the end of the first time period, typically within about 0.1 to 1 second,.
  • the variable ⁇ is described by the formula: where: i ss is the steady-state current of the second applied electric potential; and i pP is the average current over a short period of time near the end of first time period, i.e. near the end of the time during which the first electric potential is applied to the cell.
  • the average current may be the average current from 8.5 to 9.5 seconds of the 10 second long period, which is a 1.0 second time period 0.5 seconds from the end of the first time period
  • the first and second time-current transients are also employed to derive a preliminary analyte concentration value for the sample being assayed.
  • C o is the preliminary concentration of the analyte
  • F is faraday's constant, i.e. 9.6485xl0 4 C/mol
  • A is the area of the working electrode.
  • the observed first and second time-current transients are used to determine the variable ⁇ of the electrochemical cell employed in the subject method and the preliminary concentration value of the analyte of interest in the assayed physiological sample.
  • a hematocrit correction factor is determined, which hematocrit correction factor is used to obtain a hematocrit corrected analyte concentration value from the initial or preliminary analyte concentration value described above.
  • the hematocrit correction factor is a factor with which the preliminary analyte concentration (typically less a background value) may be multiplied in order to obtain a hematocrit corrected analyte concentration value, i.e. a concentration value from which the hematocrit component has been removed.
  • the hematocrit correction factor is a function of both the preliminary analyte concentration value and the variable ⁇ of the electrochemical cell.
  • any hematocrit correction factor that can be multiplied by the preliminary concentration value (usually less a background value, as described in greater detail below) may be employed in the subject methods
  • One class of hematocrit correction factors that find use in the subject methods are those that are derived from a three dimensional graph of C 0 , ⁇ and ⁇ (C 0 , ⁇ ) obtained from experimental data using a wide range of analyte and hematoc ⁇ t values
  • hematocrit corrected concentration hematocrit correction factor x[ C 0 - ⁇ ] where ⁇ is the background value
  • the above described methods yield a hematocrit corrected analyte concentration value, i e a concentration value in which the hematoc ⁇ t component has been deconvoluted and removed. As such, the above described methods provide for an accurate value of the concentration of the analyte in the sample being assayed.
  • the subject meters are typically meters for amperometrically measuring the hematocrit corrected concentration of an analyte in a physiological sample.
  • the subject meters typically include: (a) a means for applying a first electric potential to an electrochemical cell into which the sample has been introduced and measuring cell current as a function of time to obtain a first time-current transient; (b) a means for applying a second electric potential to the electrochemical cell and measuring cell current as a function of time to obtain a second time-current transient; (c) a means for determining a preliminary analyte concentration value and a variable ⁇ from said first and second time-currents; and (d) a means for removing the hematocrit component from the preliminary concentration value to derive the hematocrit corrected analyte concentration in said sample.
  • Means (a) and (b) may be any suitable means, where representative means are described in WO 97/18465 and U.S. Patent No. 5,942,102; the disclosures of which are herein incorporated by reference.
  • Means (c) and (d) are typically computing means present in the meter which are capable of using the measured first and second time current transients to ultimately obtain the hematocrit corrected analyte concentration.
  • means (c) is typically a means that is capable of determining the preliminary concentration of the analyte of interest and the variable ⁇ from the first and second time-current transients using the equations described above.
  • means (d) is typically a means that is capable of determining the hematocrit corrected analyte concentration using the equations described above, where this means typically comprises the hematocrit correction factor.
  • An electrochemical test st ⁇ p consisting of two metallized electrodes o ⁇ ented in a sandwich configuration was prepared as follows
  • the top layer of the test st ⁇ p was a gold sputtered Mylar strip
  • the middle layer was a double-sided adhesive with a punched hole that defined the reaction zone or area
  • the punched hole was a circle with two juxtaposed rectangular inlet and outlet channels
  • the bottom layer of the test st ⁇ p was sputtered palladium on Mylar A film of fern cyanide and glucose dehydrogenase PQQ was deposited on the palladium sputtered surface
  • First and second time current transients for a number of different samples varying by glucose concentration and hematocrit were obtained as follows Sample was applied to the st ⁇ p which actuated an applied potential of - 03 V for a pe ⁇ od of 10 seconds which was then followed by a second pulse of +0 3 V for a pe ⁇ od of 3 to 10 seconds (where these electrode potentials are with respect to the gold electrode)
  • C o is the preliminary concentration of the analyte
  • F is faraday's constant
  • A is the area of the electrode surface
  • variable ⁇ was derived using the equation where iss is the steady-state current of the second applied electric potential or second pulse, and ip P is the average current from 8 5 to 9 5 seconds of the 10 s long period during which the first pulse was applied
  • Hematocrit Correction Factor l/((0 6637) + ((4 9466*ln(C 0 ))/ C 0 ) + (-0 4012*ln( ⁇ ))) The above correction factor was found to be valid for those situations where the ⁇ >0 7 and Co >40 mg/dL
  • a prediction data set was generated by testing several glucose strips with a wide range of glucose and hematocrit levels From this data a hematocrit correction equation was derived using a model which fits the terms C 0 , ⁇ , and ⁇ (C 0 , ⁇ ) It was found that using the hematocrit correction equation on the prediction data set causes the majority of data points to fall within +/- 15% It was also found that the bias of the glucose results to 42%) hematoc ⁇ t, indicating that the hematocrit effect on this data set is minimal In order to confirm this algorithm, another batch of glucose sesnsors was tested with a different blood donor It was found that the algorithm still corrects for the hematocrit effect in a manner analogous to the earlier findings.

Abstract

Methods and devices for determining the concentration of an analyte in a physiological sample are provided. In the subject methods, the physiological sample is introduced into an electrochemical cell having a working and reference electrode. A first electric potential is applied to the cell and the resultant cell current over a period of time is measured to determine a first time-current transient. A second electric potential of opposite polarity is then applied and a second time-current transient is determined. The preliminary concentration of the analyte is then calculated from the first and/or second time-current transient. This preliminary analyte concentration less a background value is then multiplied by a hematocrit correction factor to obtain the analyte concentration in the sample, where the hematocrit correction factor is a function of the preliminary analyte concentration and the variable η of the electrochemical cell. The subject methods and devices are suited for use in the determination of a wide variety of analytes in a wide variety of samples, and are particularly suited for the determination of analytes in whole blood or derivatives thereof, where an analyte of particular interest is glucose.

Description

ELECTROCHEMICAL METHODS AND DEVICES FOR USE IN THE DETERMINATION OF HEMATOCRIT CORRECTED ANALYTE
CONCENTRATIONS
INTRODUCTION
Field of the Invention
The field of this invention is analyte determination, particularly electrochemical analyte determination and more particularly the electrochemical determination of blood analytes. Background
Analyte detection in physiological fluids, e g blood or blood derived products, is of ever increasing importance to today's society Analyte detection assays find use in a variety of applications, including clinical laboratory testing, home testing, etc., where the results of such testing play a prominent role in diagnosis and management in a variety of disease conditions Analytes of interest include glucose for diabetes management, cholesterol, and the like. In response to this growing importance of analyte detection, a variety of analyte detection protocols and devices for both clinical and home use have been developed.
One type of method that is employed for analyte detection is an electrochemical method. In such methods, an aqueous liquid sample is placed into a reaction zone in an electrochemical cell comprising two electrodes, i e a reference and working electrode, where the electrodes have an impedance which renders them suitable for amperometric measurement. The component to be analyzed is allowed to react directly with an electrode, or directly or indirectly with a redox reagent to form an oxidisable (or reducible) substance in an amount corresponding to the concentration of the component to be analyzed, i e. analyte The quantity of the oxidisable (or reducible) substance present is then estimated electrochemically and related to the amount of analyte present in the initial sample
Where the physiological sample being assayed is whole blood or a derivative thereof, the hematocrit of the sample can be a source of analytical error in the ultimate analyte concentration measurement For example, in electrochemical measurement protocols where the analyte concentration is derived from observed time-current transients, hematocrit can slow the equilibration chemistry in the electrochemical cell and/or slow the enzyme kinetics by increasing the sample viscosity in the cell, thereby attenuating the time current response and causing analytical error As such, there is great interest in the development of methods of at least minimizing the hematocπt originated analytical error In certain protocols, blood filteπng membranes are employed to remove red blood cells and thereby minimize the hematocπt effect These particular protocols are unsatisfactory in that increased sample volumes and testing times are required Other protocols focus on the determination of the capillary fill time However, these protocols add complexity to both the strips and devices that are used to read them In yet other embodiments, hematocrit is separately determined using two additional electrodes, which also results in more complex and expensive strips/devices
As such, there is continued interest in the identification of new methods for electrochemically measuπng the concentration of an analyte in a physiological sample, where the method minimizes the analytical error which originates with the hematocπt of the sample
Relevant Literature
Patent documents of interest include 5,942,102 and WO 97/18465
SUMMARY OF THE INVENTION Methods and devices for determining the concentration of an analyte in a physiological sample are provided In the subject methods, the physiological sample is introduced into an electrochemical cell having a working and reference electrode A first electπc potential is applied to the cell and the resultant cell current over a first peπod of time is measured to determine a first time-current transient A second electπc potential of opposite polarity is then applied to the cell and a second time-current transient is determined The preliminary concentration of the analyte (C0)ιs then calculated from the first and/or second time-current transients This preliminary analyte concentration, less a background value, is then multiplied by a hematocπt correction factor to obtain the analyte concentration in the sample, where the hematocrit correction factor is a function of the preliminary analyte concentration and the ratio of 2 current values (γ) within the time-current transient of the electrochemical cell The subject methods and devices are suited for use m the determination of a wide variety of analytes in a wide variety of samples, and are particularly suited for the determination of analytes in whole blood or derivatives thereof, where an analyte of particular interest is glucose BRIEF DESCRIPTION OF THE FIGURES Fig. 1 provides a three-dimensional graph of C0, γ and α(C0, γ) derived from experimental data using a wide range of glucose and hematocrit values.
DESCRIPTION OF THE SPECIFIC EMBODIMENTS
Methods and devices for determining the concentration of an analyte in a physiological sample are provided. In the subject methods, the physiological sample is introduced into an electrochemical cell having a working and reference electrode. A first electric potential is applied to the cell and the resultant cell current over a first period of time is measured to determine a first time-current transient. A second electric potential of opposite polarity is then applied to the cell and a second a time-current transient is determined. The preliminary concentration of the analyte is then calculated from the first and/or second time-current transient. This preliminary analyte concentration, less a background value, is then multiplied by a hematocrit correction factor to obtain the analyte concentration in the sample, where the hematocrit correction factor is a function of the preliminary analyte concentration and the variable γ of the electrochemical cell. The subject methods and devices are suited for use in the determination of a wide variety of analytes in a wide variety of samples, and are particularly suited for use in the determination of analytes in whole blood or derivatives thereof, where an analyte of particular interest is glucose. In further describing the subject invention, the subject methods will be described first followed by a review of a representative device for use in practicing the subject methods.
Before the subject invention is described further, it is to be understood that the invention is not limited to the particular embodiments of the invention described below, as variations of the particular embodiments may be made and still fall within the scope of the appended claims. It is also to be understood that the terminology employed is for the purpose of describing particular embodiments, and is not intended to be limiting. Instead, the scope of the present invention will be established by the appended claims.
In this specification and the appended claims, singular references include the plural, unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention belongs. METHODS
As summarized above, the subject invention provides a method for determining a hematocrit corrected analyte concentration value in a physiological sample. By hematocrit corrected analyte concentration is meant that the analyte concentration value determined using the subject methods has been modulated or changed to remove substantially all contribution of hematocrit to the value. In other words, the concentration value that is determined using the subject methods has been modified so that any contribution to the value from the hematocrit of the sample that would be present in the value but for the practicing of the subject methods is removed. As such, the hematocrit signal is deconvoluted from the analyte signal in the subject methods, and only the analyte signal is employed in arriving at the final hematocrit corrected analyte concentration.
The first step in the subject methods is to introduce a quantity of the physiological sample of interest into an electrochemical cell that includes spaced apart working and reference electrodes and a redox reagent system. The physiological sample may vary, but in many embodiments is generally whole blood or a derivative or fraction thereof, where whole blood is of particular interest in many embodiments. The amount of physiological sample, e.g. blood, that is introduced into the reaction area of the test strip varies, but generally ranges from about 0.1 to 10 μL, usually from about 0.9 to 1.6 μL. The sample is introduced into the reaction area using any convenient protocol, where the sample may be injected into the reaction area, allowed to wick into the reaction area, and the like, as may be convenient.
While the subject methods may be used, in principle, with any type of electrochemical cell having spaced apart working and reference electrodes and a redox reagent system, in many embodiments the subject methods employ an electrochemical test strip. The electrochemical test strips employed in these embodiments of the subject invention are made up of two opposing metal electrodes separated by a thin spacer layer, where these components define a reaction area or zone in which is located a redox reagent system.
In certain embodiments of these electrochemical test strips, the working and reference electrodes are generally configured in the form of elongated rectangular strips. Typically, the length of the electrodes ranges from about 1.9 to 4.5 cm, usually from about 2.0 to 2.8 cm. The width of the electrodes ranges from about 0.38 to 0.76 cm, usually from about 0.51 to 0.67 cm. The reference electrodes typically have a thickness ranging from about 10 to 100 nm and usually from about 10 to 20 nm. In certain embodiments, the length of one of the electrodes is shorter than the length of the other electrode, typically about 0.32 cm. The shorter electrode may be the working or reference electrode.
The working and reference electrodes are further characterized in that at least the surface of the electrodes that faces the reaction area in the strip is a metal, where metals of interest include palladium, gold, platinum, silver, iridium, carbon, doped tin oxide, stainless steel and the like. In many embodiments, the metal is gold or palladium. While in principle the entire electrode may be made of the metal, each of the electrodes is generally made up of an inert support material on the surface of which is present a thin layer of the metal component of the electrode. In these more common embodiments, the thickness of the inert backing material typically ranges from about 51 to 356 μm, usually from about 102 to
153 μm while the thickness of the metal layer typically ranges from about 10 to 100 nm and usually from about 10 to 40 nm, e.g. a sputtered metal layer. Any convenient inert backing material may be employed in the subject electrodes, where typically the material is a rigid material that is capable of providing structural support to the electrode and, in turn, the electrochemical test strip as a whole. Suitable materials that may be employed as the backing substrate include plastics, e.g. PET, PETG, polyimide, polycarbonate, polystyrene, silicon, ceramic, glass, and the like.
A feature of the electrochemical test strips used in these embodiments of the subject methods is that the working and reference electrodes as described above face each other and are separated by only a short distance, such that the distance between the working and reference electrode in the reaction zone or area of the electrochemical test strip is extremely small. This minimal spacing of the working and reference electrodes in the subject test strips is a result of the presence of a thin spacer layer positioned or sandwiched between the working and reference electrodes. The thickness of this spacer layer generally should be less than or equal to 500 μm, and usually ranges from about 102 to 153 μm. The spacer layer is cut so as to provide a reaction zone or area with at least an inlet port into the reaction zone, and generally an outlet port out of the reaction zone as well. The spacer layer may have a circular reaction area cut with side inlet and outlet vents or ports, or other configurations, e.g. square, triangular, rectangular, irregular shaped reaction areas, etc. The spacer layer may be fabricated from any convenient material, where representative suitable materials include PET, PETG, polyimide, polycarbonate, and the like, where the surfaces of the spacer layer may be treated so as to be adhesive with respect to their respective electrodes and thereby maintain the structure of the electrochemical test strip Of particular interest is the use of a die-cut double-sided adhesive stπp as the spacer layer
The electrochemical test strips used in these embodiments of the subject invention include a reaction zone or area that is defined by the working electrode, the reference electrode and the spacer layer, where these elements are described above Specifically, the working and reference electrodes define the top and bottom of the reaction area, while the spacer layer defines the walls of the reaction area The volume of the reaction area is at least about 0 1 μL, usually at least about 1 μL and more usually at least about 1 5 μL, where the volume may be as large as 10 μL or larger As mentioned above, the reaction area generally includes at least an inlet port, and in many embodiments also includes an outlet port The cross-sectional area of the inlet and outlet ports may vary as long as it is sufficiently large to provide an effective entrance or exit of fluid from the reaction area, but generally ranges from about 9 x lO^to 5 x 10"3 cm2, usually from about 1 3 x 10"3 to 2 5 x 10"3 cm2
Present in the reaction area is a redox reagent system, which reagent system provides for the species that is measured by the electrode and therefore is used to derive the concentration of analyte in a physiological sample The redox reagent system present in the reaction area typically includes at least an enzyme(s) and a mediator In many embodiments, the enzyme member(s) of the redox reagent system is an enzyme or plurality of enzymes that work in concert to oxidize the analyte of interest In other words, the enzyme component of the redox reagent system is made up of a single analyte oxidizing enzyme or a collection of two or more enzymes that work in concert to oxidize the analyte of interest Enzymes of interest include oxidases, dehydrogenases, upases, kinases, diphorases, quinoproteins, and the like
The specific enzyme present in the reaction area depends on the particular analyte for which the electrochemical test strip is designed to detect, where representative enzymes include glucose oxidase, glucose dehydrogenase, cholesterol esterase, cholesterol oxidase, lipoprotein lipase, glycerol kinase, glycerol-3-phosphate oxidase, lactate oxidase, lactate dehydrogenase, pyruvate oxidase, alcohol oxidase, bilirubin oxidase, uricase, and the like In many preferred embodiments where the analyte of interest is glucose, the enzyme component of the redox reagent system is a glucose oxidizing enzyme, e g a glucose oxidase or glucose dehydrogenase
The second component of the redox reagent system is a mediator component, which is made up of one or more mediator agents A variety of different mediator agents are known in the art and include ferπcvanide, phenazine ethosulphate, phenazine methosulfate, pheylenediamine, 1 -methoxy-phenazine methosulfate, 2,6-dιmethyl-l,4-benzoquιnone, 2,5- dιchloro-l,4-benzoquιnone, ferrocene derivatives, osmium bipyπdyl complexes, ruthenium complexes, and the like In those embodiments where glucose in the analyte of interest and glucose oxidase or glucose dehydrogenase are the enzyme components, mediators of particular interest are ferπcyanide, and the like
Other reagents that may be present in the reaction area include buffeπng agents, e g citraconate, citrate, malic, maleic, phosphate, "Good" buffers and the like Yet other agents that mav be present include divalent cations such as calcium chloride, and magnesium chloride, pyrroloquinohne quinone, types of surfactants such as Triton, Macol, Tetronic, Silwet, Zonyl, and Pluronic, stabilizing agents such as albumin, sucrose, trehalose, manmtol, and lactose
The redox reagent system is generally present in dry form The amounts of the vaπous components may vary, where the amount of enzyme component typically ranges from about 1 to 100 mg/mL, usually from about 5 to 80mg/mL, and the amount of mediator component typically ranges from about 5 to 1000 mM, usually from about 90 to 900 mM
Following sample introduction, first and second time-current transients are obtained The first and second time-current transients are obtained by applying a constant electπc potential to the cell and observing the change in current over a peπod of time in the cell In other words, first and second pulses are applied to the cell and the resultant time-current transients are observed As such, the first time-current transient is obtained by applying a constant electric potential or first pulse to the cell, e g between the working and the reference electrodes, and observing the change in current over time between the electrodes, l e change in cell current, to obtain the first time-current transient The magmtude of the first applied electric potential generally ranges from about 0 to -0 6 N, usually from about -0 2 to -0 4 N The length of time over which the current between the electrodes is observed to obtain the first time-current transient typically ranges from about 3 to 20 seconds, usually from about 4 to 10 seconds
The second time current is obtained by applying a second constant electπc potential or second pulse, typically of opposite polarity from the first constant electric potential, to the electrodes and observing the change in current between the electrodes for a second period of time The magnitude of this second constant electric potential typically ranges from about 0 to +0 6 N, usually from about +0 2 to +0 4 N, where in many embodiments the magnitude of the second electric potential is the same as the magnitude of the first electric potential. The second time period typically ranges from about 1 to 10 seconds, usually from about 2 to 4 seconds. By observing the change in current between the electrodes over this second period of time, a second time-current transient for the cell is determined. The overall time period required to obtain the requisite first and second time-current transients, as described above, is relatively short in certain embodiments. In such embodiments, the total amount of time required to obtain the first and second time-current transients is less than about 30 seconds, usually less than about 20 seconds and more usually less than about 14 seconds. The next step in the subject methods is to use the observed first and second time- current transients, obtained as described above, to determine: (a) the variable γ of the electrochemical cell used in the subject methods; and (b) a preliminary analyte concentration for the analyte of interest in the sample.
The variable γ employed in the subject methods is defined to describe the deviation of the electrochemical cell from ideality. By way of background, it should be noted that γ should approach unity under ideal conditions, i.e. reagent equilibration and glucose reaction are complete before the end of the first pulse. Any of these conditions not being complete will cause the ratio to deviate fron non-unity values. The numerator of γ is defined as the steady-state current observed following application of the second electric potential to the cell, i.e. predicted value at t=∞ of the second time-current transient. The denominator is defined as the average current over a short time period near the end of the first period of time, i.e. near the end of the application of the first electric potential or first pulse. The short period of time from which the average current is determined typically ranges from .2 to 2 seconds, usually from about .2 to 1.5 seconds and more usually from about .2 to 1.25 seconds, where in many embodiments the short period of time is about .3 second. The average current is determined at a time near the end of the first time period, typically within about 0.1 to 1 second,. In certain embodiments, the variable γ is described by the formula:
Figure imgf000009_0001
where: iss is the steady-state current of the second applied electric potential; and ipP is the average current over a short period of time near the end of first time period, i.e. near the end of the time during which the first electric potential is applied to the cell. For example, where the first time period is 10 seconds long, the average current may be the average current from 8.5 to 9.5 seconds of the 10 second long period, which is a 1.0 second time period 0.5 seconds from the end of the first time period As mentioned above, the first and second time-current transients are also employed to derive a preliminary analyte concentration value for the sample being assayed. In many embodiments, the preliminary analyte concentration is determined by using the following equations: i(t) = iss { 1 + 4 exp(-4π2Dt/L2) } iss = 2 FADCo/L where iss is the steady-state current following application of the second electric potential; i is the measured current which is a function of time
D is the diffusion coefficient of the cell, where this coefficient may be determined from Fick's first law, i.e.
Figure imgf000010_0001
L is the spacer thickness; t is the time for the application of the 2" electric potential where t=0 for the beginning of the pulse
Co is the preliminary concentration of the analyte; F is faraday's constant, i.e. 9.6485xl04C/mol; and A is the area of the working electrode.
Using the above equations and steps, the observed first and second time-current transients are used to determine the variable γ of the electrochemical cell employed in the subject method and the preliminary concentration value of the analyte of interest in the assayed physiological sample.
From the determined variable γ and preliminary analyte concentration value, a hematocrit correction factor is determined, which hematocrit correction factor is used to obtain a hematocrit corrected analyte concentration value from the initial or preliminary analyte concentration value described above. The hematocrit correction factor is a factor with which the preliminary analyte concentration (typically less a background value) may be multiplied in order to obtain a hematocrit corrected analyte concentration value, i.e. a concentration value from which the hematocrit component has been removed. The hematocrit correction factor is a function of both the preliminary analyte concentration value and the variable γ of the electrochemical cell. Any hematocrit correction factor that can be multiplied by the preliminary concentration value (usually less a background value, as described in greater detail below) may be employed in the subject methods One class of hematocrit correction factors that find use in the subject methods are those that are derived from a three dimensional graph of C0, γ and α(C0, γ) obtained from experimental data using a wide range of analyte and hematocπt values The hematocrit correction factor (α(C0, γ)) is determined using the formula (C0, γ) =actual
Figure imgf000011_0001
C0 -Background Value) (For example, where the analyte is glucose, (C0, γ) in many embodiments equals the glucose concentration as determined using the Yellow Springs Instrument glucose analyzer model 23 A (as described in U S Patent No 5, 968,760 the disclosure of which is herein incorporated by reference) divided by the C0 less a background value, e g 22 mg dL) This class of hematocrit correction factors are typically equations which fit a smooth surface function that minimizes the error between the predicted and actual data See e g the experimental section, infra One representative hematocrit correction factor that finds use in the subject methods is l/((0 6637) + ((4 9466*ln(C0))/ C0) + (-0 4012*ln(γ))) In determining the hematocπt corrected concentration of analyte according to the subject invention, the preliminary analyte concentration (C0) as determined above, less a background signal value, is multiplied by the hematocrit correction factor The background value that is subtracted from the preliminary concentration value depends on the analyte being measured For glucose, this value typically ranges from about 0 to 40 mg dL, usually from about 8 to 25 mg/dL, where in many embodiments the background value is about 22
Figure imgf000011_0002
Generally, the following formula is employed to determine the hematocrit corrected analyte concentration according to the subject invention hematocrit corrected concentration = hematocrit correction factor x[ C0 - β] where β is the background value, and
Co is the preliminary analyte concentration
The above described methods yield a hematocrit corrected analyte concentration value, i e a concentration value in which the hematocπt component has been deconvoluted and removed. As such, the above described methods provide for an accurate value of the concentration of the analyte in the sample being assayed.
The above computational steps of the subject method may be accomplished manually or through the use of an automated computing means, where in many embodiments the use of an automated computing means, such as is described in connection with the subject devices discussed below, is of interest.
DEVICES
Also provided by the subject invention are meters for use in practicing the subject invention. The subject meters are typically meters for amperometrically measuring the hematocrit corrected concentration of an analyte in a physiological sample. The subject meters typically include: (a) a means for applying a first electric potential to an electrochemical cell into which the sample has been introduced and measuring cell current as a function of time to obtain a first time-current transient; (b) a means for applying a second electric potential to the electrochemical cell and measuring cell current as a function of time to obtain a second time-current transient; (c) a means for determining a preliminary analyte concentration value and a variable γ from said first and second time-currents; and (d) a means for removing the hematocrit component from the preliminary concentration value to derive the hematocrit corrected analyte concentration in said sample. Means (a) and (b) may be any suitable means, where representative means are described in WO 97/18465 and U.S. Patent No. 5,942,102; the disclosures of which are herein incorporated by reference. Means (c) and (d) are typically computing means present in the meter which are capable of using the measured first and second time current transients to ultimately obtain the hematocrit corrected analyte concentration. As such, means (c) is typically a means that is capable of determining the preliminary concentration of the analyte of interest and the variable γ from the first and second time-current transients using the equations described above. Likewise, means (d) is typically a means that is capable of determining the hematocrit corrected analyte concentration using the equations described above, where this means typically comprises the hematocrit correction factor.
The following examples are offered by way of illustration and not by way of limitation. EXPERIMENTAL I Electrochemical Test Strip Preparation
An electrochemical test stπp consisting of two metallized electrodes oπented in a sandwich configuration was prepared as follows The top layer of the test stπp was a gold sputtered Mylar strip The middle layer was a double-sided adhesive with a punched hole that defined the reaction zone or area The punched hole was a circle with two juxtaposed rectangular inlet and outlet channels The bottom layer of the test stπp was sputtered palladium on Mylar A film of fern cyanide and glucose dehydrogenase PQQ was deposited on the palladium sputtered surface
II Generation of Experimental Data
First and second time current transients for a number of different samples varying by glucose concentration and hematocrit were obtained as follows Sample was applied to the stπp which actuated an applied potential of - 03 V for a peπod of 10 seconds which was then followed by a second pulse of +0 3 V for a peπod of 3 to 10 seconds (where these electrode potentials are with respect to the gold electrode)
HI Derivation of Hematocrit Correction Factor for Glucose
For a wide range of glucose and hematocrit values measured as descπbed above, C0, the variable γ and α(C0, γ) were derived Co was derived using the equations ι(t) = la { 1 + 4 exp(-4π2Dt/L2) } ιss = 2 FADCo/L where ιss is the steady-state current following application of the second electπc potential, l is the measured current which is a function of time
D is the diffusion coefficient of the cell, where this coefficient may be determined from Fick's first law, 1 e J(x,t)=-D dCW)ldx L is the spacer thickness, t is the time for the application of the 2nd electric potential where t=0 for the beginning of the pulse
Co is the preliminary concentration of the analyte, F is faraday's constant, I e 9 6485χ l04C/mol, and A is the area of the electrode surface
The variable γ was derived using the equation
Figure imgf000014_0001
where iss is the steady-state current of the second applied electric potential or second pulse, and ipP is the average current from 8 5 to 9 5 seconds of the 10 s long period during which the first pulse was applied
(C0, γ) was determined using the equation (C0, γ) =YSI concentration^ C0 -22 mg/dL) where YSI is the glucose concentration as determined using the Yellow Springs Instrument glucose analyzer model 23A (as described in U S Patent No 5, 968,760 the disclosure of which is herein incorporated by reference)
A three-dimensional graph of C0, γ and α(C0, γ) as determined above for a wide range of glucose and hematocrit values was prepared and is shown in Fig 1 A simple equation fit was then performed on the graph to define the surface. The residual of the fitted data was monitored to ascertain the quality of the model equation The empirical equation was found to be.
Hematocrit Correction Factor = l/((0 6637) + ((4 9466*ln(C0))/ C0) + (-0 4012*ln(γ))) The above correction factor was found to be valid for those situations where the γ >0 7 and Co >40 mg/dL
IV Comparison of Hematocrit Corrected Values to YSI determined Values
A prediction data set was generated by testing several glucose strips with a wide range of glucose and hematocrit levels From this data a hematocrit correction equation was derived using a model which fits the terms C0, γ, and α(C0, γ) It was found that using the hematocrit correction equation on the prediction data set causes the majority of data points to fall within +/- 15% It was also found that the bias of the glucose results to 42%) hematocπt, indicating that the hematocrit effect on this data set is minimal In order to confirm this algorithm, another batch of glucose sesnsors was tested with a different blood donor It was found that the algorithm still corrects for the hematocrit effect in a manner analogous to the earlier findings.
The above results and discussion demonstrate that subject invention provides a simple and powerful tool to obtain analyte concentration values in which hematocrit derived error is substantially if not entirely eliminated. As the subject methods rely solely on the measurement of time-current transients, they may be practiced with relatively simple electrochemical devices. Furthermore, only small sample volumes need be employed and relatively quick assay times are provided. As such, the subject invention represents a significant contribution to the art.
All publications and patents cited in this specification are herein incorporated by reference as if each individual publication or patent were specifically and individually indicated to be incorporated by reference. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention.
Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it is readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

Claims

WHAT IS CLAIMED IS 1 A method for determining the hematocrit corrected concentration of an analyte in a physiological sample, said method comprising (a) introducing said physiological sample into an electrochemical cell compπsing
(1) spaced apart working and reference electrodes, and
(n) a redox reagent system compπsing an enzyme and a mediator,
(b) applying a first electric potential to said reaction cell and measuπng cell current as a function of time to obtain a first time-current transient,
(c) applying a second electric potential to said cell and measuπng cell current as a function of time to obtain a second time-current transient, and
(d) deriving a preliminary analyte concentration from said first and second time- current transients, and (e) multiplying said preliminary analyte concentration less a background value by a hematocrit correction factor to derive said hematocπt corrected analyte concentration in said sample, whereby the hematocrit corrected concentration of said analyte m said sample is determined
2 The method according to Claim 1, wherein said hematocπt correction factor modulates the preliminary analyte concentration value to remove the hematocπt deπved component of said preliminary analyte concentration value
3 The method according to Claim 1, wherein said hematocπt correction factor is a function of said preliminary analyte concentration and γ of said electrochemical cell
4 The method according to Claim 1, wherein said physiological sample is whole blood or a derivative thereof
The method according to Claim 1, wherein said analyte is glucose
6 A method for determining the hematocrit corrected concentration of an analyte in a whole blood sample, said method comprising
(a) introducing said whole blood sample into an electrochemical cell comprising (i) spaced apart working and reference electrodes, and (ii) a redox reagent system comprising an enzyme and a mediator;
(b) applying a first electric potential to said reaction cell and measuring cell current as a function of time to obtain a first time-current transient,
(c) applying a second electric potential to said cell and measuring cell current as a function of time to obtain a second time-current transient, and (d) deriving a preliminary analyte concentration value from said first and second time-current transients, and
(e) multiplying said preliminary analyte concentration less a background value by a hematocrit correction factor that removes the hematocrit component from said preliminary concentration value to derive said hematocrit corrected analyte concentration in said sample, whereby the hematocrit corrected concentration of said analyte in said sample is determined
7 The method according to Claim 6, wherein said hematocrit correcting factor is a function of said preliminary analyte concentration and a variable γ of said electrochemical cell
8 The method according to Claim 6, wherein said analyte is glucose.
9 The method according to Claim 6, wherein said enzyme is an oxidizing enzyme
10 The method according to Claim 9, wherein said oxidizing enzyme is a glucose oxidizing enzyme
11 A method for determining the hematocrit corrected concentration of glucose in a whole blood sample, said method comprising
(a) introducing said whole blood sample into an electrochemical cell compπsing (1) spaced apart working and reference electrodes, and (u) a redox reagent system comprising a glucose oxidizing enzyme and a mediator,
(b) applying a first electπc potential to said reaction cell and measuπng cell current as a function of time to obtain a first time-current transient,
(c) applying a second electric potential to said cell and measuπng cell current as a function of time to obtain a second time-current transient, and
(d) deriving a preliminary glucose concentration value from said first and second time-current transients, and
(e) multiplying said preliminary glucose concentration value less a background value by a hematocπt correction factor that removes the hematocπt component from said preliminary concentration value to derive said hematocrit corrected glucose concentration in said sample, whereby the hematocπt corrected concentration of glucose in said sample is determined
12 The method according to Claim 1 1, wherein said hematocπt correction factor is a function of said preliminary analyte concentration and a variable γ of said electrochemical cell
13 The method according to Claim 12, wherein said hematocπt correction factor equals l/((0 6637) + ((4 9466*ln(C0))/ C0) + (-0 4012*ln(γ))) wherein
Co is said preliminary concentration, and γ is said variable current ratio of said electrochemical cell
14 The method according to Claim 13, wherein said preliminary glucose concentration of said sample is greater than 40 mg/dL
15. The method according to Claim 13, wherein said variable γ of said electrochemical cell is greater than 0.7.
16. A meter for amperometrically measuring the concentration of an analyte in a physiological sample, said meter comprising:
(a) means for applying a first electric potential to an electrochemical cell comprising said sample and measuring cell current as a function of time to obtain a first time-current transient;
(b) means for applying a second electric potential to said electrochemical cell and measuring cell current as a function of time to obtain a second time-current transient;
(c) means for determining a preliminary analyte concentration value and variable γ from said first and second time-currents; and
(d) means for removing the hematocrit component from said preliminary concentration value to derive said analyte concentration in said sample.
17. The meter according to Claim 16, wherein said means for removing the hematocrit component is a means for multiplying said preliminary analyte concentration value less a background value by a hematocrit correction factor.
18. The meter according to Claim 16, wherein said hematocrit correction factor is a function of said preliminary analyte concentration and said variable γ of said electrochemical cell.
19. The meter according to Claim 18, wherein said hematocrit correction factor equals: l/((0.6637) + ((4.9466*ln(C0))/ C0) + (-0.4012*ln(γ))) wherein:
C0 is said preliminary concentration; and γ is said variable current ratio of said electrochemical cell.
20. The meter according to Claim 16, wherein said analyte is glucose.
PCT/US2001/002465 2000-02-02 2001-01-25 Electrochemical methods and devices for use in the determination of hematocrit corrected analyte concentrations WO2001057510A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
AT01905055T ATE313794T1 (en) 2000-02-02 2001-01-25 ELECTROCHEMICAL METHODS AND DEVICES FOR USE IN MEASURING ANALYTE CONCENTRATIONS WITH CORRECTED HEMATOCRIT
DE60116056T DE60116056T2 (en) 2000-02-02 2001-01-25 ELECTROCHEMICAL PROCESSES AND DEVICES FOR USE IN THE MEASUREMENT OF ANALYZ CONCENTRATIONS WITH CORRECTED HAEMATOCRITING VALUE
IL14966201A IL149662A (en) 2000-02-02 2001-01-25 Electrochemical methods and devices for use in the determination of hematocrit corrected analyte concentrations
JP2001556308A JP2003521708A (en) 2000-02-02 2001-01-25 Electrochemical method and apparatus used for measurement of analyte concentration with corrected hematocrit value
EP01905055A EP1252514B1 (en) 2000-02-02 2001-01-25 Electrochemical methods and devices for use in the determination of hematocrit corrected analyte concentrations
PL01358492A PL358492A1 (en) 2000-02-02 2001-01-25 Electrochemical methods and devices for use in the determination of hematocrit corrected analyte concentrations
KR1020027009882A KR20020077409A (en) 2000-02-02 2001-01-25 Electrochemical methods and devices for use in the determination of hematocrit corrected analyte concentrations
CA002398203A CA2398203A1 (en) 2000-02-02 2001-01-25 Electrochemical methods and devices for use in the determination of hematocrit corrected analyte concentrations
AU32974/01A AU783311B2 (en) 2000-02-02 2001-01-25 Electrochemical methods and devices for use in the determination of hematocrit corrected analyte concentrations
MXPA02005797A MXPA02005797A (en) 2000-02-02 2001-01-25 Electrochemical methods and devices for use in the determination of hematocrit corrected analyte concentrations.
HK03101950.3A HK1049881B (en) 2000-02-02 2003-03-17 Electrochemical methods and devices for use in the determination of hematocrit corrected analyte concentrations
AU2006200073A AU2006200073A1 (en) 2000-02-02 2006-01-09 Electrochemical methods and devices for use in the determination of hematocrit corrected analyte concentrations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/497,304 2000-02-02
US09/497,304 US6475372B1 (en) 2000-02-02 2000-02-02 Electrochemical methods and devices for use in the determination of hematocrit corrected analyte concentrations

Publications (2)

Publication Number Publication Date
WO2001057510A2 true WO2001057510A2 (en) 2001-08-09
WO2001057510A3 WO2001057510A3 (en) 2002-02-21

Family

ID=23976305

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/002465 WO2001057510A2 (en) 2000-02-02 2001-01-25 Electrochemical methods and devices for use in the determination of hematocrit corrected analyte concentrations

Country Status (21)

Country Link
US (3) US6475372B1 (en)
EP (2) EP1252514B1 (en)
JP (1) JP2003521708A (en)
KR (1) KR20020077409A (en)
CN (1) CN1193228C (en)
AR (1) AR027345A1 (en)
AT (1) ATE313794T1 (en)
AU (1) AU783311B2 (en)
CA (1) CA2398203A1 (en)
CZ (1) CZ20021298A3 (en)
DE (1) DE60116056T2 (en)
DK (1) DK1252514T3 (en)
ES (1) ES2254368T3 (en)
HK (1) HK1049881B (en)
IL (1) IL149662A (en)
MX (1) MXPA02005797A (en)
MY (1) MY127335A (en)
PL (1) PL358492A1 (en)
RU (2) RU2262890C2 (en)
TW (1) TW520439B (en)
WO (1) WO2001057510A2 (en)

Cited By (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1281960A2 (en) 2001-08-01 2003-02-05 Lifescan, Inc. Methods and devices for use in analyte concentration determination assays
JP2003529062A (en) * 2000-03-28 2003-09-30 ダイアビ−ティ−ズ・ダイアグノスティックス・インコ−ポレイテッド Fast response glucose sensor
EP1380837A1 (en) * 2002-07-11 2004-01-14 Lifescan, Inc. Electrochemical test strip having a plurality of reaction chambers
EP1394545A1 (en) * 2002-08-27 2004-03-03 Bayer Healthcare, LLC Method of determining a haematocrit corrected glucose concentration in whole blood samples wherein the haematocrit concentration is measured by impedance spectroscopy
EP1398386A1 (en) * 2002-09-12 2004-03-17 Lifescan, Inc. Mediator stabilized reagent compositions and methods for their use in electrochemical analyte detection assays
EP1426757A1 (en) * 2001-09-14 2004-06-09 ARKRAY, Inc. Method, tool and device for measuring concentration
US6780645B2 (en) 2002-08-21 2004-08-24 Lifescan, Inc. Diagnostic kit with a memory storing test strip calibration codes and related methods
US6855243B2 (en) 2001-04-27 2005-02-15 Lifescan, Inc. Electrochemical test strip having a plurality of reaction chambers and methods for using the same
EP1770396A2 (en) * 2005-09-30 2007-04-04 Lifescan, Inc. Method and apparatus for rapid electrochemical analysis
US7276146B2 (en) 2001-11-16 2007-10-02 Roche Diagnostics Operations, Inc. Electrodes, methods, apparatuses comprising micro-electrode arrays
US7276147B2 (en) 2001-11-16 2007-10-02 Roche Diagnostics Operations, Inc. Method for determining the concentration of an analyte in a liquid sample using small volume samples and fast test times
EP1839571A1 (en) * 2006-03-31 2007-10-03 LifeScan, Inc. Methods for analyzing a sample in the presence of interferents
US7288174B2 (en) 2003-06-09 2007-10-30 I-Sens, Inc. Electrochemical biosensor
JP2008046141A (en) * 2001-11-07 2008-02-28 F Hoffmann-La Roche Ag Instrument
WO2008114060A1 (en) * 2007-03-22 2008-09-25 Quotient Diagnostics Limited Whole blood assay
WO2008141076A1 (en) * 2007-05-11 2008-11-20 Home Diagnostics, Inc. Two-pulse systems and methods for determining analyte concentration
WO2008150436A1 (en) 2007-05-31 2008-12-11 Abbott Diabetes Care Inc. Analyte determination methods and devices
EP2045597A1 (en) * 2006-10-19 2009-04-08 Panasonic Corporation Method for measuring hematocrit value of blood sample, method for measuring concentration of analyte in blood sample, sensor chip and sensor unit
EP2058651A1 (en) * 2006-10-19 2009-05-13 Panasonic Corporation Method for measuring hematocrit value of blood sample, method for measuring concentration of analyte in blood sample, sensor chip and sensor unit
EP2098857A2 (en) 2008-01-17 2009-09-09 LifeScan, Inc. System and method for measuring an analyte in a sample
US7648468B2 (en) 2002-04-19 2010-01-19 Pelikon Technologies, Inc. Method and apparatus for penetrating tissue
US7674232B2 (en) 2002-04-19 2010-03-09 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7708701B2 (en) 2002-04-19 2010-05-04 Pelikan Technologies, Inc. Method and apparatus for a multi-use body fluid sampling device
US7717863B2 (en) 2002-04-19 2010-05-18 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7727467B2 (en) 2003-06-20 2010-06-01 Roche Diagnostics Operations, Inc. Reagent stripe for test strip
US7901362B2 (en) 2002-04-19 2011-03-08 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7909983B2 (en) 2006-05-04 2011-03-22 Nipro Diagnostics, Inc. System and methods for automatically recognizing a control solution
US7955492B2 (en) 2004-04-19 2011-06-07 Panasonic Corporation Method for measuring blood components and biosensor and measuring instrument for use therein
US7972861B2 (en) 2004-05-14 2011-07-05 Bayer Healthcare Llc Methods for performing hematocrit adjustment in glucose assays and devices for same
US8071030B2 (en) 2003-06-20 2011-12-06 Roche Diagnostics Operations, Inc. Test strip with flared sample receiving chamber
US8088271B2 (en) 2003-12-04 2012-01-03 Panasonic Corporation Method of measuring hematocrit (Hct), sensor used in the method, and measuring device
US8147674B2 (en) 2007-12-10 2012-04-03 Bayer Healthcare Llc Rapid-read gated amperometry
US8262899B2 (en) 2008-07-10 2012-09-11 Bayer Healthcare Llc Systems and methods including amperometric and voltammetric duty cycles
US8267870B2 (en) 2002-04-19 2012-09-18 Sanofi-Aventis Deutschland Gmbh Method and apparatus for body fluid sampling with hybrid actuation
US8287717B2 (en) 2004-05-14 2012-10-16 Bayer Healthcare Llc Voltammetric systems for assaying biological analytes
US8287703B2 (en) 1999-10-04 2012-10-16 Roche Diagnostics Operations, Inc. Biosensor and method of making
US8298828B2 (en) 2003-06-20 2012-10-30 Roche Diagnostics Operations, Inc. System and method for determining the concentration of an analyte in a sample fluid
US8317988B2 (en) 2004-10-12 2012-11-27 Bayer Healthcare Llc Concentration determination in a diffusion barrier layer
AU2011265585B2 (en) * 2008-01-17 2013-04-18 Lifescan, Inc. System and method for measuring an analyte in a sample
WO2013069895A1 (en) 2011-11-11 2013-05-16 주식회사 아이센스 Personal blood glucose meter and abnormal measurement detection method using same
US8449740B2 (en) 2006-03-31 2013-05-28 Lifescan, Inc. Systems and methods for discriminating control solution from a physiological sample
US8507289B1 (en) 2003-06-20 2013-08-13 Roche Diagnostics Operations, Inc. System and method for coding information on a biosensor test strip
US8535497B2 (en) 2003-12-04 2013-09-17 Panasonic Corporation Method of measuring blood component, sensor used in the method, and measuring device
WO2013180528A1 (en) 2012-06-01 2013-12-05 주식회사 아이센스 Electrochemical biosensor with improved accuracy
US8663442B2 (en) 2003-06-20 2014-03-04 Roche Diagnostics Operations, Inc. System and method for analyte measurement using dose sufficiency electrodes
US8760178B2 (en) 2009-09-30 2014-06-24 Arkray, Inc. Method for measuring target component in erythrocyte-containing specimen
AU2013202716B2 (en) * 2008-01-17 2014-09-11 Lifescan, Inc. System and method for measuring an analyte in a sample
US8877035B2 (en) 2005-07-20 2014-11-04 Bayer Healthcare Llc Gated amperometry methods
GB2515299A (en) * 2013-06-18 2014-12-24 Alere Switzerland Gmbh Methods and apparatus for determining analyte in a sample
US9017544B2 (en) 2002-10-04 2015-04-28 Roche Diagnostics Operations, Inc. Determining blood glucose in a small volume sample receiving cavity and in a short time period
US9034639B2 (en) 2002-12-30 2015-05-19 Sanofi-Aventis Deutschland Gmbh Method and apparatus using optical techniques to measure analyte levels
US9072842B2 (en) 2002-04-19 2015-07-07 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US9089294B2 (en) 2002-04-19 2015-07-28 Sanofi-Aventis Deutschland Gmbh Analyte measurement device with a single shot actuator
US9157110B2 (en) 2007-09-28 2015-10-13 Lifescan, Inc. Systems and methods of discriminating control solution from a physiological sample
US9248267B2 (en) 2002-04-19 2016-02-02 Sanofi-Aventis Deustchland Gmbh Tissue penetration device
US9261476B2 (en) 2004-05-20 2016-02-16 Sanofi Sa Printable hydrogel for biosensors
WO2016092317A1 (en) * 2014-12-11 2016-06-16 Inside Biometrics Limited Method of determining parameters of a test fluid
US9410915B2 (en) 2004-06-18 2016-08-09 Roche Operations Ltd. System and method for quality assurance of a biosensor test strip
US9427532B2 (en) 2001-06-12 2016-08-30 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
WO2016207644A1 (en) * 2015-06-26 2016-12-29 Inside Biometrics Limited Electrochemical test device and method of using the same
US9561000B2 (en) 2003-12-31 2017-02-07 Sanofi-Aventis Deutschland Gmbh Method and apparatus for improving fluidic flow and sample capture
US9560993B2 (en) 2001-11-21 2017-02-07 Sanofi-Aventis Deutschland Gmbh Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means
US9694144B2 (en) 2001-06-12 2017-07-04 Sanofi-Aventis Deutschland Gmbh Sampling module device and method
US9724021B2 (en) 2002-04-19 2017-08-08 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US9784707B2 (en) 2008-06-09 2017-10-10 Lifescan, Inc. System and method for measuring an analyte in a sample
US9795747B2 (en) 2010-06-02 2017-10-24 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for lancet actuation
US9820684B2 (en) 2004-06-03 2017-11-21 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a fluid sampling device
US9835582B2 (en) 2005-09-30 2017-12-05 Ascensia Diabetes Care Holdings Ag Devices using gated voltammetry methods
US9839386B2 (en) 2002-04-19 2017-12-12 Sanofi-Aventis Deustschland Gmbh Body fluid sampling device with capacitive sensor
US9933385B2 (en) 2007-12-10 2018-04-03 Ascensia Diabetes Care Holdings Ag Method of using an electrochemical test sensor
US10034628B2 (en) 2003-06-11 2018-07-31 Sanofi-Aventis Deutschland Gmbh Low pain penetrating member
US10067082B2 (en) 2004-02-06 2018-09-04 Ascensia Diabetes Care Holdings Ag Biosensor for determining an analyte concentration
US10190150B2 (en) 2006-10-24 2019-01-29 Ascensia Diabetes Care Holdings Ag Determining analyte concentration from variant concentration distribution in measurable species
US10788441B2 (en) 2015-08-10 2020-09-29 Arkray, Inc. Measuring method of sensor using interdigitated array electrode, measuring apparatus and computer readable medium storing measuring program

Families Citing this family (187)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6036924A (en) 1997-12-04 2000-03-14 Hewlett-Packard Company Cassette of lancet cartridges for sampling blood
US8071384B2 (en) 1997-12-22 2011-12-06 Roche Diagnostics Operations, Inc. Control and calibration solutions and methods for their use
US7494816B2 (en) * 1997-12-22 2009-02-24 Roche Diagnostic Operations, Inc. System and method for determining a temperature during analyte measurement
US6391005B1 (en) 1998-03-30 2002-05-21 Agilent Technologies, Inc. Apparatus and method for penetration with shaft having a sensor for sensing penetration depth
US6554798B1 (en) 1998-08-18 2003-04-29 Medtronic Minimed, Inc. External infusion device with remote programming, bolus estimator and/or vibration alarm capabilities
US6591125B1 (en) 2000-06-27 2003-07-08 Therasense, Inc. Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator
US6475372B1 (en) * 2000-02-02 2002-11-05 Lifescan, Inc. Electrochemical methods and devices for use in the determination of hematocrit corrected analyte concentrations
EP1152239A4 (en) * 1999-11-15 2009-05-27 Panasonic Corp Biosensor, method of forming thin-film electrode, and method and apparatus for quantitative determination
US20020092612A1 (en) * 2000-03-28 2002-07-18 Davies Oliver William Hardwicke Rapid response glucose sensor
AU2006209265B2 (en) * 2000-03-28 2010-05-13 Diabetes Diagnostics, Inc. Rapid response glucose sensor
EP2096437B1 (en) 2000-11-30 2014-11-19 Panasonic Healthcare Co., Ltd. Biosensor for quantifying substrate
CA2448905C (en) 2001-06-12 2010-09-07 Pelikan Technologies, Inc. Blood sampling apparatus and method
US9226699B2 (en) 2002-04-19 2016-01-05 Sanofi-Aventis Deutschland Gmbh Body fluid sampling module with a continuous compression tissue interface surface
ES2352998T3 (en) 2001-06-12 2011-02-24 Pelikan Technologies Inc. LANCETA ELECTRIC ACTUATOR.
CA2448902C (en) 2001-06-12 2010-09-07 Pelikan Technologies, Inc. Self optimizing lancing device with adaptation means to temporal variations in cutaneous properties
AU2002344825A1 (en) 2001-06-12 2002-12-23 Pelikan Technologies, Inc. Method and apparatus for improving success rate of blood yield from a fingerstick
US8337419B2 (en) 2002-04-19 2012-12-25 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US7981056B2 (en) 2002-04-19 2011-07-19 Pelikan Technologies, Inc. Methods and apparatus for lancet actuation
WO2002100254A2 (en) 2001-06-12 2002-12-19 Pelikan Technologies, Inc. Method and apparatus for lancet launching device integrated onto a blood-sampling cartridge
US6872358B2 (en) 2002-01-16 2005-03-29 Lifescan, Inc. Test strip dispenser
US8260393B2 (en) 2003-07-25 2012-09-04 Dexcom, Inc. Systems and methods for replacing signal data artifacts in a glucose sensor data stream
US8010174B2 (en) 2003-08-22 2011-08-30 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US20030212379A1 (en) * 2002-02-26 2003-11-13 Bylund Adam David Systems and methods for remotely controlling medication infusion and analyte monitoring
US20030186446A1 (en) 2002-04-02 2003-10-02 Jerry Pugh Test strip containers and methods of using the same
US7976476B2 (en) 2002-04-19 2011-07-12 Pelikan Technologies, Inc. Device and method for variable speed lancet
US7892183B2 (en) 2002-04-19 2011-02-22 Pelikan Technologies, Inc. Method and apparatus for body fluid sampling and analyte sensing
US7547287B2 (en) 2002-04-19 2009-06-16 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7491178B2 (en) 2002-04-19 2009-02-17 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7232451B2 (en) 2002-04-19 2007-06-19 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7297122B2 (en) 2002-04-19 2007-11-20 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7331931B2 (en) 2002-04-19 2008-02-19 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7291117B2 (en) 2002-04-19 2007-11-06 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8360992B2 (en) 2002-04-19 2013-01-29 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8372016B2 (en) 2002-04-19 2013-02-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for body fluid sampling and analyte sensing
US7909778B2 (en) 2002-04-19 2011-03-22 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8221334B2 (en) 2002-04-19 2012-07-17 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7175642B2 (en) 2002-04-19 2007-02-13 Pelikan Technologies, Inc. Methods and apparatus for lancet actuation
US7371247B2 (en) 2002-04-19 2008-05-13 Pelikan Technologies, Inc Method and apparatus for penetrating tissue
US9314194B2 (en) 2002-04-19 2016-04-19 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US7229458B2 (en) 2002-04-19 2007-06-12 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7343188B2 (en) * 2002-05-09 2008-03-11 Lifescan, Inc. Devices and methods for accessing and analyzing physiological fluid
US20050049522A1 (en) * 2002-10-30 2005-03-03 Allen John J Method of lancing skin for the extraction of blood
AU2003900285A0 (en) * 2003-01-20 2003-02-06 Universal Biosensors Pty Limited Electrochemical detection method
US20050176133A1 (en) * 2003-02-21 2005-08-11 Matsushita Electric Industrial Co., Ltd. Measuring instrument for biosensor and measuring method using same
US20040193202A1 (en) * 2003-03-28 2004-09-30 Allen John J. Integrated lance and strip for analyte measurement
US7473264B2 (en) * 2003-03-28 2009-01-06 Lifescan, Inc. Integrated lance and strip for analyte measurement
US20040193072A1 (en) * 2003-03-28 2004-09-30 Allen John J. Method of analyte measurement using integrated lance and strip
EP2238892A3 (en) 2003-05-30 2011-02-09 Pelikan Technologies Inc. Apparatus for body fluid sampling
US7850621B2 (en) 2003-06-06 2010-12-14 Pelikan Technologies, Inc. Method and apparatus for body fluid sampling and analyte sensing
US7488601B2 (en) 2003-06-20 2009-02-10 Roche Diagnostic Operations, Inc. System and method for determining an abused sensor during analyte measurement
US7645421B2 (en) 2003-06-20 2010-01-12 Roche Diagnostics Operations, Inc. System and method for coding information on a biosensor test strip
US8206565B2 (en) 2003-06-20 2012-06-26 Roche Diagnostics Operation, Inc. System and method for coding information on a biosensor test strip
US8679853B2 (en) 2003-06-20 2014-03-25 Roche Diagnostics Operations, Inc. Biosensor with laser-sealed capillary space and method of making
US7645373B2 (en) 2003-06-20 2010-01-12 Roche Diagnostic Operations, Inc. System and method for coding information on a biosensor test strip
US7718439B2 (en) 2003-06-20 2010-05-18 Roche Diagnostics Operations, Inc. System and method for coding information on a biosensor test strip
US7220034B2 (en) * 2003-07-11 2007-05-22 Rudolph Technologies, Inc. Fiber optic darkfield ring light
US8282549B2 (en) 2003-12-09 2012-10-09 Dexcom, Inc. Signal processing for continuous analyte sensor
US20190357827A1 (en) 2003-08-01 2019-11-28 Dexcom, Inc. Analyte sensor
US20080119703A1 (en) 2006-10-04 2008-05-22 Mark Brister Analyte sensor
US20140121989A1 (en) 2003-08-22 2014-05-01 Dexcom, Inc. Systems and methods for processing analyte sensor data
US7920906B2 (en) 2005-03-10 2011-04-05 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US7682833B2 (en) 2003-09-10 2010-03-23 Abbott Point Of Care Inc. Immunoassay device with improved sample closure
US7723099B2 (en) 2003-09-10 2010-05-25 Abbott Point Of Care Inc. Immunoassay device with immuno-reference electrode
WO2005033659A2 (en) 2003-09-29 2005-04-14 Pelikan Technologies, Inc. Method and apparatus for an improved sample capture device
WO2005037095A1 (en) 2003-10-14 2005-04-28 Pelikan Technologies, Inc. Method and apparatus for a variable user interface
JP4704351B2 (en) 2003-11-06 2011-06-15 ライフスキャン・インコーポレイテッド Drug introduction pen with event notification means
US9247900B2 (en) 2004-07-13 2016-02-02 Dexcom, Inc. Analyte sensor
US8287453B2 (en) 2003-12-05 2012-10-16 Dexcom, Inc. Analyte sensor
US8423114B2 (en) 2006-10-04 2013-04-16 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US20100185071A1 (en) * 2003-12-05 2010-07-22 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US11633133B2 (en) 2003-12-05 2023-04-25 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US8364231B2 (en) 2006-10-04 2013-01-29 Dexcom, Inc. Analyte sensor
EP2256493B1 (en) 2003-12-05 2014-02-26 DexCom, Inc. Calibration techniques for a continuous analyte sensor
US7822454B1 (en) 2005-01-03 2010-10-26 Pelikan Technologies, Inc. Fluid sampling device with improved analyte detecting member configuration
US20050187525A1 (en) * 2004-02-19 2005-08-25 Hilgers Michael E. Devices and methods for extracting bodily fluid
ES2588178T3 (en) * 2004-03-31 2016-10-31 Ascensia Diabetes Care Holding Ag Method to implement correction functions based on a threshold for biosensors
AU2012238249B2 (en) * 2004-05-14 2015-03-12 Ascensia Diabetes Care Holdings Ag Voltammetric systems for assaying biological analytes
DE602005013957D1 (en) 2004-06-03 2009-05-28 Meso Scale Technologies Llc METHOD FOR PERFORMING FULL BLOOD TESTS
US9775553B2 (en) 2004-06-03 2017-10-03 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a fluid sampling device
US20050284773A1 (en) * 2004-06-29 2005-12-29 Allen John J Method of preventing reuse in an analyte measuring system
US20050284757A1 (en) * 2004-06-29 2005-12-29 Allen John J Analyte measuring system which prevents the reuse of a test strip
US20060000710A1 (en) 2004-06-30 2006-01-05 Klaus Peter Weidenhaupt Fluid handling methods
US8170803B2 (en) 2004-07-13 2012-05-01 Dexcom, Inc. Transcutaneous analyte sensor
US8652831B2 (en) 2004-12-30 2014-02-18 Sanofi-Aventis Deutschland Gmbh Method and apparatus for analyte measurement test time
GB0503836D0 (en) 2005-02-24 2005-04-06 Axis Shield Asa Method
US7547382B2 (en) 2005-04-15 2009-06-16 Agamatrix, Inc. Determination of partial fill in electrochemical strips
US7964089B2 (en) 2005-04-15 2011-06-21 Agamatrix, Inc. Analyte determination method and analyte meter
US8323464B2 (en) * 2005-05-25 2012-12-04 Universal Biosensors Pty Ltd Method and apparatus for electrochemical analysis
US8016154B2 (en) * 2005-05-25 2011-09-13 Lifescan, Inc. Sensor dispenser device and method of use
US8192599B2 (en) * 2005-05-25 2012-06-05 Universal Biosensors Pty Ltd Method and apparatus for electrochemical analysis
US20060281187A1 (en) 2005-06-13 2006-12-14 Rosedale Medical, Inc. Analyte detection devices and methods with hematocrit/volume correction and feedback control
CA2624059C (en) 2005-09-30 2019-04-02 Intuity Medical, Inc. Multi-site body fluid sampling and analysis cartridge
US7955484B2 (en) * 2005-12-14 2011-06-07 Nova Biomedical Corporation Glucose biosensor and method
US8219173B2 (en) 2008-09-30 2012-07-10 Abbott Diabetes Care Inc. Optimizing analyte sensor calibration
US7653425B2 (en) 2006-08-09 2010-01-26 Abbott Diabetes Care Inc. Method and system for providing calibration of an analyte sensor in an analyte monitoring system
US20070235346A1 (en) * 2006-04-11 2007-10-11 Popovich Natasha D System and methods for providing corrected analyte concentration measurements
US20080083618A1 (en) * 2006-09-05 2008-04-10 Neel Gary T System and Methods for Determining an Analyte Concentration Incorporating a Hematocrit Correction
CA2664186C (en) 2006-09-22 2021-02-23 Bayer Healthcare Llc Biosensor system having enhanced stability and hematocrit performance
EP2082222B1 (en) 2006-10-05 2012-11-21 Lifescan Scotland Limited Systems and methods for determining a substantially hematocrit independent analyte concentration
US9046480B2 (en) 2006-10-05 2015-06-02 Lifescan Scotland Limited Method for determining hematocrit corrected analyte concentrations
GB0711780D0 (en) * 2007-06-18 2007-07-25 Oxford Biosensors Ltd Electrochemical data rejection methodology
AU2008279070B2 (en) * 2007-07-26 2012-12-13 Nipro Diagnostics, Inc. System and methods for determination of analyte concentration using time resolved amperometry
JP5273680B2 (en) * 2007-09-18 2013-08-28 国立大学法人東京農工大学 Enzyme electrode
US8001825B2 (en) * 2007-11-30 2011-08-23 Lifescan, Inc. Auto-calibrating metering system and method of use
CN103760356B (en) * 2007-12-10 2019-06-28 安晟信医疗科技控股公司 Slope-based compensation
EP2232250A1 (en) * 2007-12-10 2010-09-29 Bayer HealthCare LLC Methods and systems for forming reagent with reduced background current
US20090145775A1 (en) 2007-12-10 2009-06-11 Bayer Healthcare Llc Reagents and methods for detecting analytes
USD612279S1 (en) 2008-01-18 2010-03-23 Lifescan Scotland Limited User interface in an analyte meter
KR100967621B1 (en) 2008-01-22 2010-07-05 전남대학교산학협력단 The method for reducing measurement error using kinetic changing information and the apparatus thereof
IL197532A0 (en) 2008-03-21 2009-12-24 Lifescan Scotland Ltd Analyte testing method and system
USD611853S1 (en) 2008-03-21 2010-03-16 Lifescan Scotland Limited Analyte test meter
USD615431S1 (en) 2008-03-21 2010-05-11 Lifescan Scotland Limited Analyte test meter
USD612275S1 (en) 2008-03-21 2010-03-23 Lifescan Scotland, Ltd. Analyte test meter
US8008037B2 (en) 2008-03-27 2011-08-30 Roche Diagnostics Operations, Inc. Matrix composition with alkylphenazine quaternary salt and a nitrosoaniline
US9386944B2 (en) 2008-04-11 2016-07-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for analyte detecting device
WO2009145920A1 (en) 2008-05-30 2009-12-03 Intuity Medical, Inc. Body fluid sampling device -- sampling site interface
CA2726067C (en) 2008-06-06 2020-10-20 Intuity Medical, Inc. Detection meter and mode of operation
USD611151S1 (en) 2008-06-10 2010-03-02 Lifescan Scotland, Ltd. Test meter
USD611489S1 (en) 2008-07-25 2010-03-09 Lifescan, Inc. User interface display for a glucose meter
USD611372S1 (en) 2008-09-19 2010-03-09 Lifescan Scotland Limited Analyte test meter
CA2738731A1 (en) * 2008-09-30 2010-04-08 Menai Medical Technologies Limited Sample measurement system
CN102239406A (en) 2008-12-08 2011-11-09 拜尔健康护理有限责任公司 Biosensor system with signal adjustment
US9375169B2 (en) 2009-01-30 2016-06-28 Sanofi-Aventis Deutschland Gmbh Cam drive for managing disposable penetrating member actions with a single motor and motor and control system
EP3973855A1 (en) 2009-06-30 2022-03-30 Lifescan, Inc. Analyte testing methods and device for calculating basal insulin therapy
US20100332445A1 (en) * 2009-06-30 2010-12-30 Lifescan, Inc. Analyte testing method and system
BRPI1015133A2 (en) * 2009-06-30 2016-04-19 Lifescan Scotland Ltd diabetes management systems and methods
RU2606769C2 (en) * 2009-09-04 2017-01-10 Лайфскэн Скотлэнд Лимитед Glucose measurement method and system
CA3077994C (en) 2009-09-29 2022-06-21 Lifescan Scotland Limited Analyte testing method and device for diabetes management
US8545693B2 (en) * 2009-09-29 2013-10-01 Lifescan Scotland Limited Analyte measurment method and system
JP5350960B2 (en) 2009-09-30 2013-11-27 アークレイ株式会社 Method for measuring target components in erythrocyte-containing samples
EP2506768B1 (en) 2009-11-30 2016-07-06 Intuity Medical, Inc. Calibration material delivery devices and methods
AU2010330821B2 (en) * 2009-12-18 2014-05-08 Abbott Point Of Care Inc. Integrated hinged cartridge housings for sample analysis
US8101065B2 (en) 2009-12-30 2012-01-24 Lifescan, Inc. Systems, devices, and methods for improving accuracy of biosensors using fill time
US8877034B2 (en) 2009-12-30 2014-11-04 Lifescan, Inc. Systems, devices, and methods for measuring whole blood hematocrit based on initial fill velocity
AU2012200759B2 (en) * 2009-12-30 2014-07-24 Lifescan, Inc. Systems, devices and methods for improving accuracy of biosensors using fill time
US8844725B2 (en) * 2010-01-20 2014-09-30 Roche Diagnostics Operations, Inc. Test strip container with strip retainer and methods of manufacturing and utilization thereof
CN102770868B (en) 2010-02-25 2017-02-22 生命扫描苏格兰有限公司 Analyte testing method and system with high and low blood glucose trends notification
US8742773B2 (en) 2010-02-25 2014-06-03 Lifescan Scotland Limited Capacitance detection in electrochemical assay with improved response
CA2790912A1 (en) 2010-02-25 2011-09-01 Lifescan Scotland Limited Analyte testing method and system with safety warnings for insulin dosing
US8773106B2 (en) 2010-02-25 2014-07-08 Lifescan Scotland Limited Capacitance detection in electrochemical assay with improved sampling time offset
ES2456899T3 (en) 2010-02-25 2014-04-23 Lifescan Scotland Limited Capacitance detection in electrochemical test
US20110208435A1 (en) 2010-02-25 2011-08-25 Lifescan Scotland Ltd. Capacitance detection in electrochemical assays
US10591436B2 (en) * 2010-03-22 2020-03-17 Ascensia Diabetes Care Holdings Ag Residual compensation including underfill error
GB201005357D0 (en) 2010-03-30 2010-05-12 Menai Medical Technologies Ltd Sampling plate
GB201005359D0 (en) 2010-03-30 2010-05-12 Menai Medical Technologies Ltd Sampling plate
US8965476B2 (en) 2010-04-16 2015-02-24 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US8394343B2 (en) 2010-04-27 2013-03-12 Roche Diagnostics Operations, Inc. Integrated test strip container with retaining insert
US20110278321A1 (en) 2010-05-11 2011-11-17 Roche Diagnostics Operations, Inc. Hermetically sealed test strip container
KR101971233B1 (en) 2010-06-07 2019-04-22 바이엘 헬쓰케어 엘엘씨 Slope-based compensation including secondary output signals
CN103025242B (en) 2010-06-30 2015-12-09 生命扫描苏格兰有限公司 Guarantee about average before the meal with the mthods, systems and devices of the statistical power of GLPP difference Message Transmission
US8932445B2 (en) 2010-09-30 2015-01-13 Cilag Gmbh International Systems and methods for improved stability of electrochemical sensors
US8617370B2 (en) 2010-09-30 2013-12-31 Cilag Gmbh International Systems and methods of discriminating between a control sample and a test fluid using capacitance
US8349612B2 (en) 2010-11-15 2013-01-08 Roche Diagnostics Operations, Inc. Guided structured testing kit
DK3575796T3 (en) 2011-04-15 2021-01-18 Dexcom Inc ADVANCED ANALYZE SENSOR CALIBRATION AND ERROR DETECTION
EP4339613A2 (en) 2011-08-03 2024-03-20 Intuity Medical, Inc. Body fluid sampling arrangement
ES2757909T3 (en) 2011-09-21 2020-04-30 Ascensia Diabetes Care Holdings Ag Compensation analysis including segmented signals
KR101333225B1 (en) * 2011-10-27 2013-11-26 광주과학기술원 Method and apparatus for measuring hematocrit
US9903830B2 (en) 2011-12-29 2018-02-27 Lifescan Scotland Limited Accurate analyte measurements for electrochemical test strip based on sensed physical characteristic(s) of the sample containing the analyte
ES2656497T3 (en) 2012-03-30 2018-02-27 Lifescan Scotland Limited Method of detecting battery and storage status and system in medical control
US9625465B2 (en) 2012-05-15 2017-04-18 Defined Diagnostics, Llc Clinical diagnostic systems
US9075042B2 (en) 2012-05-15 2015-07-07 Wellstat Diagnostics, Llc Diagnostic systems and cartridges
US9213043B2 (en) 2012-05-15 2015-12-15 Wellstat Diagnostics, Llc Clinical diagnostic system including instrument and cartridge
WO2014052136A1 (en) 2012-09-26 2014-04-03 Abbott Diabetes Care Inc. Method and apparatus for improving lag correction during in vivo measurement of analyte concentration with analyte concentration variability and range data
US9005426B2 (en) 2012-09-28 2015-04-14 Cilag Gmbh International System and method for determining hematocrit insensitive glucose concentration
US9080196B2 (en) 2012-09-28 2015-07-14 Cilag Gmbh International System and method for determining hematocrit insensitive glucose concentration
US9005901B2 (en) * 2013-03-15 2015-04-14 Abbott Laboratories Assay with internal calibration
US9435762B2 (en) 2013-06-27 2016-09-06 Lifescan Scotland Limited Fill error trap for an analyte measurement determined from a specified sampling time derived from a sensed physical characteristic of the sample containing the analyte
US9835578B2 (en) 2013-06-27 2017-12-05 Lifescan Scotland Limited Temperature compensation for an analyte measurement determined from a specified sampling time derived from a sensed physical characteristic of the sample containing the analyte
US9435764B2 (en) 2013-06-27 2016-09-06 Lifescan Scotland Limited Transient signal error trap for an analyte measurement determined from a specified sampling time derived from a sensed physical characteristic of the sample containing the analyte
TWI576583B (en) * 2013-08-02 2017-04-01 達爾生技股份有限公司 Determination methods for biochemical detection strips
US9459231B2 (en) 2013-08-29 2016-10-04 Lifescan Scotland Limited Method and system to determine erroneous measurement signals during a test measurement sequence
US9243276B2 (en) 2013-08-29 2016-01-26 Lifescan Scotland Limited Method and system to determine hematocrit-insensitive glucose values in a fluid sample
US9828621B2 (en) 2013-09-10 2017-11-28 Lifescan Scotland Limited Anomalous signal error trap for an analyte measurement determined from a specified sampling time derived from a sensed physical characteristic of the sample containing the analyte
WO2015061598A1 (en) 2013-10-24 2015-04-30 Quidel Corporation Systems and methods for whole blood assays
DE102013227125B4 (en) 2013-12-23 2016-04-07 Senslab-Gesellschaft Zur Entwicklung Und Herstellung Bioelektrochemischer Sensoren Mbh A method for determining a hematocrit-dependent measurement signal in the determination of an analyte from whole blood using single-use enzymatic-voltammetric sensors
RU2548778C1 (en) * 2014-02-10 2015-04-20 Виталий Юрьевич Мишланов Diagnostic technique for blood serum glucose, total protein and electrolytes by multi-frequency impedance analysis
DE202014100630U1 (en) 2014-02-13 2014-02-18 Sanofi-Aventis Deutschland Gmbh gauge
KR101666978B1 (en) 2014-09-17 2016-10-24 주식회사 아이센스 Apparatus and Method for measuring concentration of Whole Blood Samples Using the same
US20160091451A1 (en) 2014-09-25 2016-03-31 Lifescan Scotland Limited Accurate analyte measurements for electrochemical test strip to determine analyte measurement time based on measured temperature, physical characteristic and estimated analyte value
US20160091450A1 (en) 2014-09-25 2016-03-31 Lifescan Scotland Limited Accurate analyte measurements for electrochemical test strip to determine analyte measurement time based on measured temperature, physical characteristic and estimated analyte value and their temperature compensated values
GB2531728A (en) 2014-10-27 2016-05-04 Cilag Gmbh Int Method for determining diffusion
EP3088880A1 (en) 2015-04-28 2016-11-02 Industrial Technology Research Institute Methods for measuring analyte concentration
JP6553554B2 (en) * 2015-08-10 2019-07-31 アークレイ株式会社 Measuring method, measuring apparatus and measuring program for sensor using comb-shaped electrode
CN105891297B (en) * 2016-05-09 2018-07-06 三诺生物传感股份有限公司 A kind of electrochemical measuring method
CN109270145B (en) * 2018-11-20 2021-09-17 三诺生物传感股份有限公司 Method for testing electrochemical test strip with double electrodes
CN111812175B (en) * 2020-06-30 2022-06-14 江苏鱼跃医疗设备股份有限公司 Blood detection method for reducing interference of hematocrit and biosensor
CN114371195B (en) * 2021-12-31 2023-06-30 无锡博慧斯生物医药科技有限公司 Correction method for hematocrit

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0735363A1 (en) * 1991-10-18 1996-10-02 Matsushita Electric Industrial Co., Ltd. A biosensor and a method for measuring a concentration of a substrate in a sample
WO1999032881A1 (en) * 1997-12-22 1999-07-01 Roche Diagnostics Corporation Meter
EP0928967A2 (en) * 1998-01-06 1999-07-14 Kyoto Daiichi Kagaku Co., Ltd. Method and apparatus for the determination of a substance coexisting with another substance
US5942102A (en) * 1995-11-16 1999-08-24 Usf Filtration And Separations Group Inc. Electrochemical method
WO1999060391A1 (en) * 1998-05-20 1999-11-25 Arkray, Inc. Method and apparatus for electrochemical measurement using statistical technique

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089320A (en) * 1989-01-09 1992-02-18 James River Ii, Inc. Resealable packaging material
US5353351A (en) * 1992-06-09 1994-10-04 At&T Bell Laboratories Secure teleconferencing
US5437999A (en) * 1994-02-22 1995-08-01 Boehringer Mannheim Corporation Electrochemical sensor
US5628890A (en) * 1995-09-27 1997-05-13 Medisense, Inc. Electrochemical sensor
US5633169A (en) * 1995-10-27 1997-05-27 Nova Biomedical Corporation Measurement of carbon dioxide in blood
US6475372B1 (en) * 2000-02-02 2002-11-05 Lifescan, Inc. Electrochemical methods and devices for use in the determination of hematocrit corrected analyte concentrations
US6287451B1 (en) * 1999-06-02 2001-09-11 Handani Winarta Disposable sensor and method of making
US20020092612A1 (en) * 2000-03-28 2002-07-18 Davies Oliver William Hardwicke Rapid response glucose sensor

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0735363A1 (en) * 1991-10-18 1996-10-02 Matsushita Electric Industrial Co., Ltd. A biosensor and a method for measuring a concentration of a substrate in a sample
US5942102A (en) * 1995-11-16 1999-08-24 Usf Filtration And Separations Group Inc. Electrochemical method
WO1999032881A1 (en) * 1997-12-22 1999-07-01 Roche Diagnostics Corporation Meter
EP0928967A2 (en) * 1998-01-06 1999-07-14 Kyoto Daiichi Kagaku Co., Ltd. Method and apparatus for the determination of a substance coexisting with another substance
WO1999060391A1 (en) * 1998-05-20 1999-11-25 Arkray, Inc. Method and apparatus for electrochemical measurement using statistical technique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1252514A2 *

Cited By (168)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8287703B2 (en) 1999-10-04 2012-10-16 Roche Diagnostics Operations, Inc. Biosensor and method of making
US8551308B2 (en) 1999-10-04 2013-10-08 Roche Diagnostics Operations, Inc. Biosensor and method of making
JP2003529062A (en) * 2000-03-28 2003-09-30 ダイアビ−ティ−ズ・ダイアグノスティックス・インコ−ポレイテッド Fast response glucose sensor
US6855243B2 (en) 2001-04-27 2005-02-15 Lifescan, Inc. Electrochemical test strip having a plurality of reaction chambers and methods for using the same
US9937298B2 (en) 2001-06-12 2018-04-10 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US9802007B2 (en) 2001-06-12 2017-10-31 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for lancet actuation
US9694144B2 (en) 2001-06-12 2017-07-04 Sanofi-Aventis Deutschland Gmbh Sampling module device and method
US9427532B2 (en) 2001-06-12 2016-08-30 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
EP1281960A2 (en) 2001-08-01 2003-02-05 Lifescan, Inc. Methods and devices for use in analyte concentration determination assays
EP1426757A4 (en) * 2001-09-14 2005-09-28 Arkray Inc Method, tool and device for measuring concentration
USRE45764E1 (en) 2001-09-14 2015-10-20 Arkray, Inc. Concentration measuring method, concentration test instrument, and concentration measuring apparatus
US7390391B2 (en) 2001-09-14 2008-06-24 Arkray, Inc. Concentration measuring method, concentration test instrument, and concentration measuring apparatus
USRE44522E1 (en) 2001-09-14 2013-10-08 Arkray, Inc. Concentration measuring method, concentration test instrument, and concentration measuring apparatus
EP1426757A1 (en) * 2001-09-14 2004-06-09 ARKRAY, Inc. Method, tool and device for measuring concentration
EP2330407A1 (en) * 2001-09-14 2011-06-08 ARKRAY, Inc. Method, tool and device for measuring concentration
EP1456666B1 (en) * 2001-11-07 2012-07-18 Roche Diagnostics GmbH Method for the determination of glucose
JP2008046141A (en) * 2001-11-07 2008-02-28 F Hoffmann-La Roche Ag Instrument
US9658183B2 (en) 2001-11-16 2017-05-23 Roche Diabetes Care, Inc. Method for determining the concentration of an analyte in a liquid sample using small volume samples and fast test times
US10386322B2 (en) 2001-11-16 2019-08-20 Roche Diabetes Care, Inc. Method for determining the concentration of an analyte in a liquid sample using small volume samples and fast test times
US9017543B2 (en) 2001-11-16 2015-04-28 Roche Diagnostics Operations, Inc. Method for determining the concentration of an analyte in a liquid sample using small volume samples and fast test times
US7276146B2 (en) 2001-11-16 2007-10-02 Roche Diagnostics Operations, Inc. Electrodes, methods, apparatuses comprising micro-electrode arrays
US7276147B2 (en) 2001-11-16 2007-10-02 Roche Diagnostics Operations, Inc. Method for determining the concentration of an analyte in a liquid sample using small volume samples and fast test times
US9560993B2 (en) 2001-11-21 2017-02-07 Sanofi-Aventis Deutschland Gmbh Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means
US7648468B2 (en) 2002-04-19 2010-01-19 Pelikon Technologies, Inc. Method and apparatus for penetrating tissue
US9186468B2 (en) 2002-04-19 2015-11-17 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US9724021B2 (en) 2002-04-19 2017-08-08 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8267870B2 (en) 2002-04-19 2012-09-18 Sanofi-Aventis Deutschland Gmbh Method and apparatus for body fluid sampling with hybrid actuation
US7674232B2 (en) 2002-04-19 2010-03-09 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US9907502B2 (en) 2002-04-19 2018-03-06 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7708701B2 (en) 2002-04-19 2010-05-04 Pelikan Technologies, Inc. Method and apparatus for a multi-use body fluid sampling device
US7713214B2 (en) 2002-04-19 2010-05-11 Pelikan Technologies, Inc. Method and apparatus for a multi-use body fluid sampling device with optical analyte sensing
US7717863B2 (en) 2002-04-19 2010-05-18 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US9795334B2 (en) 2002-04-19 2017-10-24 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US9498160B2 (en) 2002-04-19 2016-11-22 Sanofi-Aventis Deutschland Gmbh Method for penetrating tissue
US7901362B2 (en) 2002-04-19 2011-03-08 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US9248267B2 (en) 2002-04-19 2016-02-02 Sanofi-Aventis Deustchland Gmbh Tissue penetration device
US9072842B2 (en) 2002-04-19 2015-07-07 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US9839386B2 (en) 2002-04-19 2017-12-12 Sanofi-Aventis Deustschland Gmbh Body fluid sampling device with capacitive sensor
US9089294B2 (en) 2002-04-19 2015-07-28 Sanofi-Aventis Deutschland Gmbh Analyte measurement device with a single shot actuator
US9089678B2 (en) 2002-04-19 2015-07-28 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
EP1380837A1 (en) * 2002-07-11 2004-01-14 Lifescan, Inc. Electrochemical test strip having a plurality of reaction chambers
US6780645B2 (en) 2002-08-21 2004-08-24 Lifescan, Inc. Diagnostic kit with a memory storing test strip calibration codes and related methods
EP1394545A1 (en) * 2002-08-27 2004-03-03 Bayer Healthcare, LLC Method of determining a haematocrit corrected glucose concentration in whole blood samples wherein the haematocrit concentration is measured by impedance spectroscopy
US7291256B2 (en) 2002-09-12 2007-11-06 Lifescan, Inc. Mediator stabilized reagent compositions and methods for their use in electrochemical analyte detection assays
EP1398386A1 (en) * 2002-09-12 2004-03-17 Lifescan, Inc. Mediator stabilized reagent compositions and methods for their use in electrochemical analyte detection assays
US10408784B2 (en) 2002-10-04 2019-09-10 Roche Diabetes Care, Inc. Determining blood glucose in a small volume sample receiving cavity and in a short time period
US9017544B2 (en) 2002-10-04 2015-04-28 Roche Diagnostics Operations, Inc. Determining blood glucose in a small volume sample receiving cavity and in a short time period
US9638658B2 (en) 2002-10-04 2017-05-02 Roche Diabetes Care, Inc. Determining blood glucose in a small volume sample receiving cavity and in a short time period
US9034639B2 (en) 2002-12-30 2015-05-19 Sanofi-Aventis Deutschland Gmbh Method and apparatus using optical techniques to measure analyte levels
US7288174B2 (en) 2003-06-09 2007-10-30 I-Sens, Inc. Electrochemical biosensor
US10034628B2 (en) 2003-06-11 2018-07-31 Sanofi-Aventis Deutschland Gmbh Low pain penetrating member
US7879618B2 (en) 2003-06-20 2011-02-01 Roche Diagnostics Operations, Inc. Method and reagent for producing narrow, homogenous reagent strips
US8211379B2 (en) 2003-06-20 2012-07-03 Roche Diagnostics Operations, Inc. Test strip with slot vent opening
US7727467B2 (en) 2003-06-20 2010-06-01 Roche Diagnostics Operations, Inc. Reagent stripe for test strip
US7829023B2 (en) 2003-06-20 2010-11-09 Roche Diagnostics Operations, Inc. Test strip with vent opening
US8298828B2 (en) 2003-06-20 2012-10-30 Roche Diagnostics Operations, Inc. System and method for determining the concentration of an analyte in a sample fluid
US8119414B2 (en) 2003-06-20 2012-02-21 Roche Diagnostics Operations, Inc. Test strip with slot vent opening
US8142721B2 (en) 2003-06-20 2012-03-27 Roche Diagnostics Operations, Inc. Test strip with slot vent opening
US8663442B2 (en) 2003-06-20 2014-03-04 Roche Diagnostics Operations, Inc. System and method for analyte measurement using dose sufficiency electrodes
US8507289B1 (en) 2003-06-20 2013-08-13 Roche Diagnostics Operations, Inc. System and method for coding information on a biosensor test strip
US8586373B2 (en) 2003-06-20 2013-11-19 Roche Diagnostics Operations, Inc. System and method for determining the concentration of an analyte in a sample fluid
US7749437B2 (en) 2003-06-20 2010-07-06 Roche Diagnostics Operations, Inc. Method and reagent for producing narrow, homogenous reagent stripes
US8071030B2 (en) 2003-06-20 2011-12-06 Roche Diagnostics Operations, Inc. Test strip with flared sample receiving chamber
US8222044B2 (en) 2003-06-20 2012-07-17 Roche Diagnostics Operations, Inc. Test strip with flared sample receiving chamber
US8535497B2 (en) 2003-12-04 2013-09-17 Panasonic Corporation Method of measuring blood component, sensor used in the method, and measuring device
US8480869B2 (en) 2003-12-04 2013-07-09 Panasonic Corporation Method of measuring hematocrit (Hct), sensor used in the method, and measuring device
US8540864B2 (en) 2003-12-04 2013-09-24 Panasonic Corporation Method of measuring blood component, sensor used in the method, and measuring device
US9719956B2 (en) 2003-12-04 2017-08-01 Panasonic Healthcare Holdings Co., Ltd. Method of measuring blood component, sensor used in the method, and measuring device
US8088271B2 (en) 2003-12-04 2012-01-03 Panasonic Corporation Method of measuring hematocrit (Hct), sensor used in the method, and measuring device
US9213012B2 (en) 2003-12-04 2015-12-15 Panasonic Healthcare Holdings Co., Ltd. Method of measuring blood component, sensor used in the method, and measuring device
US9561000B2 (en) 2003-12-31 2017-02-07 Sanofi-Aventis Deutschland Gmbh Method and apparatus for improving fluidic flow and sample capture
US10067082B2 (en) 2004-02-06 2018-09-04 Ascensia Diabetes Care Holdings Ag Biosensor for determining an analyte concentration
US9285335B2 (en) 2004-04-19 2016-03-15 Panasonic Healthcare Holdings Co., Ltd. Method for measuring blood components and biosensor and measuring instrument for use therein
US8524055B2 (en) 2004-04-19 2013-09-03 Panasonic Corporation Method for measuring blood components and biosensor and measuring instrument for use therein
US7955492B2 (en) 2004-04-19 2011-06-07 Panasonic Corporation Method for measuring blood components and biosensor and measuring instrument for use therein
US7972861B2 (en) 2004-05-14 2011-07-05 Bayer Healthcare Llc Methods for performing hematocrit adjustment in glucose assays and devices for same
US8287717B2 (en) 2004-05-14 2012-10-16 Bayer Healthcare Llc Voltammetric systems for assaying biological analytes
US9784706B2 (en) 2004-05-14 2017-10-10 Ascensia Diabetes Care Holdings Ag Voltammetric systems for assaying biological analytes
US8871079B2 (en) 2004-05-14 2014-10-28 Bayer Healthcare Llc Voltammetric systems for assaying biological analytes
US10416110B2 (en) 2004-05-14 2019-09-17 Ascensia Diabetes Care Holdings Ag Voltammetric systems for assaying biological analytes
US9261476B2 (en) 2004-05-20 2016-02-16 Sanofi Sa Printable hydrogel for biosensors
US9820684B2 (en) 2004-06-03 2017-11-21 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a fluid sampling device
US9410915B2 (en) 2004-06-18 2016-08-09 Roche Operations Ltd. System and method for quality assurance of a biosensor test strip
US9546974B2 (en) 2004-10-12 2017-01-17 Ascensia Diabetes Care Holdings Ag Concentration determination in a diffusion barrier layer
US8317988B2 (en) 2004-10-12 2012-11-27 Bayer Healthcare Llc Concentration determination in a diffusion barrier layer
US9206460B2 (en) 2004-10-12 2015-12-08 Bayer Healthcare Llc Concentration determination in a diffusion barrier layer
US8852422B2 (en) 2004-10-12 2014-10-07 Bayer Healthcare Llc Concentration determination in a diffusion barrier layer
US8877035B2 (en) 2005-07-20 2014-11-04 Bayer Healthcare Llc Gated amperometry methods
EP3483599A1 (en) 2005-07-20 2019-05-15 Ascensia Diabetes Care Holdings AG Methods for measuring the concentration of an analyte in solution and for calibrating the measurement as well as handheld devices therefor
EP1770396A2 (en) * 2005-09-30 2007-04-04 Lifescan, Inc. Method and apparatus for rapid electrochemical analysis
US8404102B2 (en) 2005-09-30 2013-03-26 Lifescan, Inc. Method and apparatus for rapid electrochemical analysis
EP3138490A1 (en) * 2005-09-30 2017-03-08 Lifescan, Inc. Method for rapid electrochemical analysis
EP1770396A3 (en) * 2005-09-30 2008-04-09 Lifescan, Inc. Method and apparatus for rapid electrochemical analysis
EP3483598A1 (en) 2005-09-30 2019-05-15 Ascensia Diabetes Care Holdings AG Gated voltammetry
US9835582B2 (en) 2005-09-30 2017-12-05 Ascensia Diabetes Care Holdings Ag Devices using gated voltammetry methods
US11435312B2 (en) 2005-09-30 2022-09-06 Ascensia Diabetes Care Holdings Ag Devices using gated voltammetry methods
US10670553B2 (en) 2005-09-30 2020-06-02 Ascensia Diabetes Care Holdings Ag Devices using gated voltammetry methods
US7749371B2 (en) 2005-09-30 2010-07-06 Lifescan, Inc. Method and apparatus for rapid electrochemical analysis
EP2280276A3 (en) * 2005-09-30 2011-04-06 LifeScan, Inc. Method and apparatus for rapid electrochemical analysis
EP2278330A3 (en) * 2005-09-30 2011-04-06 LifeScan, Inc. Method and apparatus for rapid electrochemical analysis
US9274078B2 (en) 2006-03-31 2016-03-01 Lifescan, Inc. Systems and methods of discriminating control solution from a physiological sample
EP1839571A1 (en) * 2006-03-31 2007-10-03 LifeScan, Inc. Methods for analyzing a sample in the presence of interferents
US8529751B2 (en) 2006-03-31 2013-09-10 Lifescan, Inc. Systems and methods for discriminating control solution from a physiological sample
EP2266455A1 (en) * 2006-03-31 2010-12-29 LifeScan, Inc. Methods for analyzing a sample in the presence of interferents
EP2263521A1 (en) * 2006-03-31 2010-12-22 LifeScan, Inc. Methods for analyzing a sample in the presence of interferents
EP2263522A1 (en) * 2006-03-31 2010-12-22 LifeScan, Inc. Methods for analyzing a sample in the presence of interferents
US8163162B2 (en) 2006-03-31 2012-04-24 Lifescan, Inc. Methods and apparatus for analyzing a sample in the presence of interferents
US8449740B2 (en) 2006-03-31 2013-05-28 Lifescan, Inc. Systems and methods for discriminating control solution from a physiological sample
AU2007201378B2 (en) * 2006-03-31 2009-09-03 Lifescan, Inc. Methods and apparatus for analyzing a sample in the presence of interferents
US7909983B2 (en) 2006-05-04 2011-03-22 Nipro Diagnostics, Inc. System and methods for automatically recognizing a control solution
EP2045597A1 (en) * 2006-10-19 2009-04-08 Panasonic Corporation Method for measuring hematocrit value of blood sample, method for measuring concentration of analyte in blood sample, sensor chip and sensor unit
EP2058651A4 (en) * 2006-10-19 2012-04-04 Panasonic Corp Method for measuring hematocrit value of blood sample, method for measuring concentration of analyte in blood sample, sensor chip and sensor unit
US9244037B2 (en) 2006-10-19 2016-01-26 Panasonic Healthcare Holdings Co., Ltd. Method for measuring hematocrit value of blood sample, method for measuring concentration of analyte in blood sample, sensor chip and sensor unit
EP2058651A1 (en) * 2006-10-19 2009-05-13 Panasonic Corporation Method for measuring hematocrit value of blood sample, method for measuring concentration of analyte in blood sample, sensor chip and sensor unit
US9958411B2 (en) 2006-10-19 2018-05-01 Panasonic Healthcare Holdings Co., Ltd. Method for measuring hematocrit value of blood sample, method for measuring concentration of analyte in blood sample, sensor chip and sensor unit
US10866205B2 (en) 2006-10-19 2020-12-15 Phc Holdings Corporation Method for measuring hematocrit value of blood sample, method for measuring concentration of analyte in blood sample, sensor chip and sensor unit
US8691072B2 (en) 2006-10-19 2014-04-08 Panasonic Corporation Method for measuring hematocrit value of blood sample, method for measuring concentration of analyte in blood sample, sensor chip and sensor unit
EP2045597A4 (en) * 2006-10-19 2012-04-04 Panasonic Corp Method for measuring hematocrit value of blood sample, method for measuring concentration of analyte in blood sample, sensor chip and sensor unit
US11091790B2 (en) 2006-10-24 2021-08-17 Ascensia Diabetes Care Holdings Ag Determining analyte concentration from variant concentration distribution in measurable species
US10190150B2 (en) 2006-10-24 2019-01-29 Ascensia Diabetes Care Holdings Ag Determining analyte concentration from variant concentration distribution in measurable species
US7943331B2 (en) 2007-03-22 2011-05-17 Quotient Diagnostics Limited Whole blood assay
WO2008114060A1 (en) * 2007-03-22 2008-09-25 Quotient Diagnostics Limited Whole blood assay
WO2008141076A1 (en) * 2007-05-11 2008-11-20 Home Diagnostics, Inc. Two-pulse systems and methods for determining analyte concentration
US8414759B2 (en) 2007-05-31 2013-04-09 Abbott Diabetes Care Inc. Analyte determination methods and devices
EP2164981A4 (en) * 2007-05-31 2010-07-21 Abbott Diabetes Care Inc Analyte determination methods and devices
EP2164981A1 (en) * 2007-05-31 2010-03-24 Abbott Diabetes Care Inc. Analyte determination methods and devices
US8083925B2 (en) 2007-05-31 2011-12-27 Abbott Diabetes Care Inc. Analyte determination methods and devices
WO2008150436A1 (en) 2007-05-31 2008-12-11 Abbott Diabetes Care Inc. Analyte determination methods and devices
US8080153B2 (en) 2007-05-31 2011-12-20 Abbott Diabetes Care Inc. Analyte determination methods and devices
US9157110B2 (en) 2007-09-28 2015-10-13 Lifescan, Inc. Systems and methods of discriminating control solution from a physiological sample
EP3690058A1 (en) 2007-12-10 2020-08-05 Ascensia Diabetes Care Holdings AG Handheld measurement device for rapid-read gated amperometry
US9034160B2 (en) 2007-12-10 2015-05-19 Bayer Healthcare Llc Rapid-read gated amperometry devices
US10908112B2 (en) 2007-12-10 2021-02-02 Ascensia Diabetes Care Holdings Ag Rapid-read gated amperometry devices
US9933385B2 (en) 2007-12-10 2018-04-03 Ascensia Diabetes Care Holdings Ag Method of using an electrochemical test sensor
US8147674B2 (en) 2007-12-10 2012-04-03 Bayer Healthcare Llc Rapid-read gated amperometry
EP3395954A1 (en) 2007-12-10 2018-10-31 Ascensia Diabetes Care Holdings AG Rapid-read gated amperometry
US10690614B2 (en) 2007-12-10 2020-06-23 Ascensia Diabetes Care Holdings Ag Method of using an electrochemical test sensor
US10345255B2 (en) 2007-12-10 2019-07-09 Ascensia Diabetes Care Holdings Ag Rapid-read gated amperometry devices
US8709739B2 (en) 2008-01-17 2014-04-29 Lifescan, Inc. System and method for measuring an analyte in a sample
EP2098857A3 (en) * 2008-01-17 2009-12-30 LifeScan, Inc. System and method for measuring an analyte in a sample
AU2009200097B2 (en) * 2008-01-17 2011-01-06 Lifescan, Inc. System and method for measuring an analyte in a sample
US8916040B2 (en) 2008-01-17 2014-12-23 Lifescan, Inc. System and method for measuring an analyte in a sample
KR101102265B1 (en) 2008-01-17 2012-01-03 라이프스캔, 인코포레이티드 System and method for measuring an analyte in a sample
AU2013202716B2 (en) * 2008-01-17 2014-09-11 Lifescan, Inc. System and method for measuring an analyte in a sample
US9739749B2 (en) 2008-01-17 2017-08-22 Lifescan, Inc. System and method for measuring an analyte in a sample
US8603768B2 (en) 2008-01-17 2013-12-10 Lifescan, Inc. System and method for measuring an analyte in a sample
AU2011201199B2 (en) * 2008-01-17 2011-09-29 Lifescan, Inc. System and method for measuring an analyte in a sample
AU2011265585B2 (en) * 2008-01-17 2013-04-18 Lifescan, Inc. System and method for measuring an analyte in a sample
EP3187867A1 (en) * 2008-01-17 2017-07-05 Lifescan, Inc. System and method for measuring an analyte in a sample
EP2098857A2 (en) 2008-01-17 2009-09-09 LifeScan, Inc. System and method for measuring an analyte in a sample
US9784707B2 (en) 2008-06-09 2017-10-10 Lifescan, Inc. System and method for measuring an analyte in a sample
US8262899B2 (en) 2008-07-10 2012-09-11 Bayer Healthcare Llc Systems and methods including amperometric and voltammetric duty cycles
US8871070B2 (en) 2008-07-10 2014-10-28 Bayer Healthcare Llc Systems, methods, and devices including amperometric and voltammetric duty cycles
US9726632B2 (en) 2008-07-10 2017-08-08 Ascensia Diabetes Care Holdings Ag Identifying ionizable species with voltammetric duty cycles
US9228978B2 (en) 2008-07-10 2016-01-05 Bayer Healthcare Llc Identifying ionizable species with voltammetric duty cycles
US10989683B2 (en) 2008-07-10 2021-04-27 Ascensia Diabetes Care Holdings Ag Identifying ionizable species with voltammetric duty cycles
US10444178B2 (en) 2008-07-10 2019-10-15 Ascensia Diabetes Care Holdings Ag Method for measuring an analyte in a sample
US8760178B2 (en) 2009-09-30 2014-06-24 Arkray, Inc. Method for measuring target component in erythrocyte-containing specimen
US9795747B2 (en) 2010-06-02 2017-10-24 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for lancet actuation
WO2013069895A1 (en) 2011-11-11 2013-05-16 주식회사 아이센스 Personal blood glucose meter and abnormal measurement detection method using same
US9753004B2 (en) 2012-06-01 2017-09-05 I-Sens, Inc. Electrochemical biosensor with improved accuracy
WO2013180528A1 (en) 2012-06-01 2013-12-05 주식회사 아이센스 Electrochemical biosensor with improved accuracy
US9873902B2 (en) 2013-06-18 2018-01-23 Suresensors Limited Methods and apparatus for determining analyte in a sample using a sensor having electrodes which are provided with an enzyme and a mediator
GB2515299B (en) * 2013-06-18 2015-12-30 Suresensors Ltd Methods and apparatus for determining analyte in a sample
GB2515299A (en) * 2013-06-18 2014-12-24 Alere Switzerland Gmbh Methods and apparatus for determining analyte in a sample
WO2016092317A1 (en) * 2014-12-11 2016-06-16 Inside Biometrics Limited Method of determining parameters of a test fluid
WO2016207644A1 (en) * 2015-06-26 2016-12-29 Inside Biometrics Limited Electrochemical test device and method of using the same
US10788441B2 (en) 2015-08-10 2020-09-29 Arkray, Inc. Measuring method of sensor using interdigitated array electrode, measuring apparatus and computer readable medium storing measuring program

Also Published As

Publication number Publication date
AU783311B2 (en) 2005-10-13
HK1049881A1 (en) 2003-05-30
PL358492A1 (en) 2004-08-09
RU2002116217A (en) 2004-01-20
AU3297401A (en) 2001-08-14
DK1252514T3 (en) 2006-05-01
US6475372B1 (en) 2002-11-05
EP1252514A2 (en) 2002-10-30
EP1645876A2 (en) 2006-04-12
MXPA02005797A (en) 2003-10-14
CN1394280A (en) 2003-01-29
CZ20021298A3 (en) 2003-05-14
EP1645876A3 (en) 2008-03-05
HK1049881B (en) 2006-09-08
WO2001057510A3 (en) 2002-02-21
RU2005123794A (en) 2007-02-10
CN1193228C (en) 2005-03-16
US20050176153A1 (en) 2005-08-11
US20020125145A1 (en) 2002-09-12
EP1252514B1 (en) 2005-12-21
TW520439B (en) 2003-02-11
ES2254368T3 (en) 2006-06-16
KR20020077409A (en) 2002-10-11
MY127335A (en) 2006-11-30
JP2003521708A (en) 2003-07-15
RU2262890C2 (en) 2005-10-27
IL149662A (en) 2005-07-25
IL149662A0 (en) 2002-11-10
ATE313794T1 (en) 2006-01-15
AR027345A1 (en) 2003-03-26
DE60116056D1 (en) 2006-01-26
US6890421B2 (en) 2005-05-10
CA2398203A1 (en) 2001-08-09
DE60116056T2 (en) 2006-08-10

Similar Documents

Publication Publication Date Title
US6475372B1 (en) Electrochemical methods and devices for use in the determination of hematocrit corrected analyte concentrations
US6855243B2 (en) Electrochemical test strip having a plurality of reaction chambers and methods for using the same
EP1770396B1 (en) Method for rapid electrochemical analysis
CN107091870B (en) Determine measuring device, bio-sensor system and the method for analyte concentration
EP1839571A1 (en) Methods for analyzing a sample in the presence of interferents
JP2003185615A (en) Determination of sample volume adequacy
EP2812444B1 (en) Electrochemical-based analytical test strip with fill-speed configured reagent layer
AU2006200073A1 (en) Electrochemical methods and devices for use in the determination of hematocrit corrected analyte concentrations
EP1380837A1 (en) Electrochemical test strip having a plurality of reaction chambers
JP2011506967A (en) Method and system for producing a reagent with reduced background current
IL150669A (en) Electrochemical test strip having a plurality of reaction chambers and methods for using the same
AU2002300361A1 (en) Electrochemical test strip having a plurality of reaction chambers and methods for using the same
KR20040007028A (en) Electrochemical test strip having a plurality of reaction chambers and methods for using the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 32974/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PV2002-1298

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 1020027005916

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2001905055

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 149662

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/833/CHE

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/005797

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2002 2002116217

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 018034373

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2398203

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020027009882

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2001 556308

Country of ref document: JP

Kind code of ref document: A

WWW Wipo information: withdrawn in national office

Ref document number: 1020027005916

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1020027009882

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2001905055

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2002-1298

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 167301

Country of ref document: IL

WWG Wipo information: grant in national office

Ref document number: 2001905055

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 32974/01

Country of ref document: AU